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The objectives of this study were to determine: the effects of maternal melatonin
(MEL) supplementation during late gestation on the histological and molecular
regulation in the Longissimus dorsi (LM) muscle of fetal bovine offspring, composition
and gene expression of fetal perirenal (PR) adipose tissue, and LM gene expression in
postnatal offspring at birth and d 195 of age. Maternal supplementation of MEL during
late gestation resulted in no difference in calf fetal body weight or birth weight. However,
at d 195 of age, calves from MEL treated dams had an average body weight increase of
20 kg. Fetal LM weight and length tended to be increased in calves from MEL treated
dams. Fetal gene expression of calves from MEL treated dams resulted in: increased LM
adenosine monophosphate-activated protein kinase-α (AMPK) and decreased PR
adiponectin (ADIPOQ), CCAAT enhancer binding protein alpha (CEBPA), proliferator
activated receptor gamma (PPARg), and stearoyl-CoA desaturase (SCD). The improved
metabolic status of LM coupled with the decrease in adipogenic gene expression, could
result in calves from MEL treated dams having improved lean muscle accretion and
reduced overall adiposity during postnatal development.

ACKNOWLEDGEMENTS
First, I would like to acknowledge my committee members, Dr.’s Derris Burnett,
Caleb Lemley, Trent Smith and Mark Crenshaw, for their contributions to my research
project. I’d especially like to thank Dr. Derris Burnett who has given me the opportunity
to grow as a scientist through his guidance and support. I would like to give a special
thanks to Dr. Caleb Lemley for helping me anytime that I needed extra support. I’d like
to thank all the graduate students who have helped me along this journey. Lastly, I would
like to thank my fiancé, Jamee Moran, for helping me countless hours on my research
project and for encouraging me to always do my best, no matter how daunting the task.

ii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS ................................................................................................ ii
LIST OF TABLES .............................................................................................................. v
LIST OF FIGURES ......................................................................................................... viii
CHAPTER
I.

INTRODUCTION .................................................................................................1
1.1

II.

LITURATURE REVIEW .....................................................................................7
2.1
2.2
2.3
2.4
2.5
2.6

III.

References .................................................................................................4

Fetal Programming in Humans and Livestock ..........................................7
Muscle Development in Cattle ................................................................10
Adipose Development in Cattle...............................................................13
Intramuscular Fibrogenesis in Cattle .......................................................16
Therapeutic Melatonin Supplementation in Normal and
Compromised Pregnancies ......................................................................17
References ...............................................................................................21

EFFECT OF MATERNAL MELATONIN SUPPLEMENTATION
DURING LATE GESTATION ON MUSCLE AND ADIPOSE TISSUE
HISTOLOGY, GENE EXPRESSION IN 240 DAY OLD BOVINE
FETUSES ............................................................................................................32
3.1
3.2
3.3

Abstract....................................................................................................32
Introduction .............................................................................................33
Materials and Methods ............................................................................37
3.3.1 Animal Care and Treatment ..............................................................37
3.3.2 Cesarean Section ...............................................................................38
3.3.3 Analysis of Fatty Acids .....................................................................38
3.3.4 Longissimus dorsi Analysis of Relative Gene Expression ................40
3.3.4.1 QuantiNova™ SYBR® Green PCR Kit .......................................40
3.3.4.2 TaqMan™ fast advanced master mix ..........................................41
3.3.5 Perirenal Adipose Analysis of Relative Gene Expression ................42
3.3.6 Analysis of Longissimus dorsi Immunohistochemistry ....................43
3.3.7 Statistical Analysis ............................................................................45
iii

3.4

Results .....................................................................................................46
3.4.1 Fatty Acid Analysis ...........................................................................46
3.4.2 Fetal Morphometric Analysis ............................................................47
3.4.3 Fetal Longissimus dorsi Relative Gene Expression Analysis ...........47
3.4.4 Fetal Perirenal Fat Relative Gene Expression Analysis ....................48
3.4.5 Fetal Longissimus dorsi IHC Analysis ..............................................48
3.5
Discussion................................................................................................49
3.6
References .............................................................................................112
IV.

EFFECT OF MATERNAL MELATONIN SUPPLEMENTATION
DURING LATE GESTATION ON NEONATAL LOIN MUSCLE
GENE EXPRESSION DURING EARLY POSTNATAL LIFE ......................120
4.1
4.2
4.3

Abstract..................................................................................................120
Introduction ...........................................................................................121
Materials and Methods ..........................................................................124
4.3.1 Animal Care and Treatment ............................................................124
4.3.2 Longissimus dorsi biopsy collection ...............................................125
4.3.3 Longissimus dorsi Analysis of Relative Gene Expression ..............126
4.3.3.1 QuantiNova™ SYBR® Green PCR Kit .....................................126
4.3.3.2 TaqMan™ fast advanced master mix ........................................127
4.3.4 Statistical Analysis ..........................................................................129
4.4
Results ...................................................................................................129
4.4.1 D 0 Morphometric Analysis ............................................................129
4.4.2 D 0 Longissimus dorsi Relative Gene Expression Analysis ...........129
4.4.3 Day 195 Morphometric Analysis ....................................................130
4.4.4 Day 195 Longissimus dorsi Relative Gene Expression
Analysis ...........................................................................................130
4.5
Discussion..............................................................................................130
4.6
References .............................................................................................154

iv

LIST OF TABLES
3.1

Accession, sequences, amplicon length, and efficiency of primers
used for QuantiNovaTM SYBR® Green real-time PCR quantification
of Longissimus dorsi gene expression. ...........................................................54

3.2

Assays, accession, amplicon length, and efficiency of primers used
for TaqMan® real-time PCR quantification of Longissimus dorsi gene
expression. ......................................................................................................55

3.3

Assays, accession, amplicon length, and efficiency of primers used
for TaqMan® real-time PCR quantification of perirenal adipose tissue
gene expression. .............................................................................................56

3.4

Fetal umbilical artery composition of saturated (SFA),
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA)
of calves CON (n=6), MEL (n=6). .................................................................57

3.5

Fetal umbilical artery composition in percent of saturated (SFA),
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA)
of calves CON (n=6), MEL (n=6). .................................................................58

3.6

Fetal umbilical vein composition of saturated (SFA),
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA)
of calves CON (n=6), MEL (n=6). .................................................................59

3.7

Fetal umbilical vein composition in percent of saturated (SFA),
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA)
of calves CON (n=6), MEL (n=6). .................................................................60

3.8

Fetal perirenal fat composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA) of calves CON
(n=6), MEL (n=6). ..........................................................................................61

3.9

Fetal perirenal fat composition in percent of saturated (SFA),
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA)
of calves CON (n=6), MEL (n=6). .................................................................62

3.10

Fetal trunk plasma composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA) of calves CON
(n=6), MEL (n=6). ..........................................................................................63
v

3.11

Fetal trunk plasma composition in percent of saturated (SFA),
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA)
of calves CON (n=6), MEL (n=6). .................................................................64

3.12

Maternal plasma composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA) of calves CON
(n=6), MEL (n=6). ..........................................................................................65

3.13

Maternal plasma composition in percent of saturated (SFA),
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA)
of calves CON (n=6), MEL (n=6). .................................................................66

3.14

Fetal morphometrics with body weight (BW; kg) and Longissimus
dorsi (LM) weight (kg), circumference (cm), and length (cm) of
muscle and perirenal (PR) adipose tissue weight (kg) for calves CON
(n=6), MEL (n=6). ..........................................................................................67

3.15

QuantiNovaTM SYBR® Green real-time PCR quantification of Fetal
Longissimus dorsi (LM) PCR relative expression of IGF1, IGF1R,
IGF2, IGF2R, BMP, CYS, LOX, and AMPK of calves CON (n=6),
MEL (n=6). .....................................................................................................68

3.16

TaqMan® real-time PCR quantification of Fetal Longissimus dorsi
(LM) PCR relative expression of IGF1, IGF1R, IGF2, IGF2R, BMP,
CYS, LOX, and AMPK of calves CON (n=6), MEL (n=6). ..........................69

3.17

Fetal perirenal adipose tissue (PR) PCR relative expression of
ADIPOQ, IGF1, and UCP1 of calves CON (n=6), MEL (n=6). ....................70

3.18

Fetal immunohistochemistry of Longissimus dorsi (LM) with number
of primary to secondary fibers (Prime:Sec), number of PAX7
activated nuclei to total nuclei (PAX7:Nuclei), total number of nuclei
to number of myofibers (Nuclei:Fiber ), and cross-sectional areas of
primary and secondary fibers (Prime CSA; Sec CSA) of calves CON
(n=6), MEL (n=6). ..........................................................................................71

4.1

Accession, sequences, amplicon length, and efficiency of primers
used for QuantiNovaTM SYBR® Green real-time PCR quantification
of Longissimus dorsi gene expression. .........................................................135

4.2

Assays, accession, amplicon length, and efficiency of primers used
for TaqMan® real-time PCR quantification of Longissimus dorsi gene
expression. ....................................................................................................136

4.3

Morphometric body weight measurements of newborn (d0) calves
and at 195 days of age (d195) from heifers and cows treated with
CON (n=17) and MEL (n=18)......................................................................137
vi

4.4

QuantiNovaTM SYBR® Green real-time PCR quantification of day 0
and day 195 of age calf Longissimus dorsi (LM) PCR relative
expression of IGF1, IGF1R, IGF2, IGF2R, BMP, CYS, LOX, and
AMPK of calves CON (n=15) and MEL (n=12). .........................................138

4.5

TaqMan® real-time PCR quantification of Fetal Longissimus dorsi
(LM) PCR relative expression of IGF1, IGF1R, IGF2, IGF2R, BMP,
CYS, LOX, and AMPK of calves CON (n=15) and MEL (n=12). ..............139

vii

LIST OF FIGURES
3.1

Fetal umbilical artery composition of saturated (SFA),
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA),
in milligrams per kilogram, from fetuses harvested from CON (n=6)
vs. MEL (n=6) treated dams. ..........................................................................72

3.2

Fetal umbilical vein composition of saturated (SFA),
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA),
in milligrams per kilogram, from fetuses harvested from CON (n=6)
vs. MEL (n=6) treated dams. ..........................................................................73

3.3

Fetal perirenal fat composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA), in milligrams per
kilogram, from fetuses harvested from CON (n=6) vs. MEL (n=6)
treated dams. ...................................................................................................74

3.4

Fetal trunk plasma composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA), in milligrams per
kilogram, from fetuses harvested from CON (n=6) vs. MEL (n=6)
treated dams. ...................................................................................................75

3.5

Maternal plasma composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA), in milligrams per
kilogram, from fetuses harvested from CON (n=6) vs. MEL (n=6)
treated dams. ...................................................................................................76

3.6

Body weight average from fetuses harvested from CON (n=6) vs.
MEL (n=6) treated dams. ...............................................................................77

3.7

Fetal Longissimus dorsi average weight (kg) from fetuses harvested
from CON (n=6) vs. MEL (n=6) treated dams. x–y Means within a row
without common superscript represent tendencies (P ≥ 0.05 and P ≤
0.10) ................................................................................................................78

3.8

Fetal Longissimus dorsi average circumference (cm) from fetuses
harvested from CON (n=6) vs. MEL (n=6) treated dams. x–y Means
within a row without common superscript represent tendencies (P ≥
0.05 and P ≤ 0.10) ..........................................................................................79
viii

3.9

Fetal Longissimus dorsi average length (cm) from fetuses harvested
from CON (n=6) vs. MEL (n=6) treated dams. x–y Means within a row
without common superscript represent tendencies (P ≥ 0.05 and P ≤
0.10) ................................................................................................................80

3.10

Fetal perirenal adipose tissue average weight (kg) from fetuses
harvested from CON (n=6) vs. MEL (n=6) treated dams. .............................81

3.11

Relative expression (mRNA abundance) of Insulin-Like Growth
factor 1 in Longissimus dorsi, from fetuses harvested from CON
(n=6) vs. MEL (n=6) treated dams. ................................................................82

3.12

Relative expression (mRNA abundance) of Insulin-Like Growth
factor 1 receptor in Longissimus dorsi, from fetuses harvested from
CON (n=6) vs. MEL (n=6) treated dams. ......................................................83

3.13

Relative expression (mRNA abundance) of Insulin-Like Growth
factor 2 in Longissimus dorsi, from fetuses harvested from CON
(n=6) vs. MEL (n=6) treated dams. ................................................................84

3.14

Relative expression (mRNA abundance) of Insulin-Like Growth
factor 2 receptor in Longissimus dorsi, from fetuses harvested from
CON (n=6) vs. MEL (n=6) treated dams. ......................................................85

3.15

Relative expression (mRNA abundance) of bone morphogenetic
protein in Longissimus dorsi, from fetuses harvested from CON (n=6)
vs. MEL (n=6) treated dams. ..........................................................................86

3.16

Relative expression (mRNA abundance) of cystatin in Longissimus
dorsi, from fetuses harvested from CON (n=6) vs. MEL (n=6) treated
dams. a–b Means within a row without common superscript differ (P <
0.05) ................................................................................................................87

3.17

Relative expression (mRNA abundance) of lysyl oxidase in
Longissimus dorsi, from fetuses harvested from CON (n=6) vs. MEL
(n=6) treated dams. .........................................................................................88

3.18

Fetal Relative expression (mRNA abundance) of adenosine
monophosphate-activated protein kinase-α in Longissimus dorsi, from
fetuses harvested from CON (n=6) vs. MEL (n=6) treated dams. a–b
Means within a row without common superscript differ (P < 0.05) ..............89

3.19

Fetal Relative expression (mRNA abundance) of myogenic factor 5 in
Longissimus dorsi, from fetuses harvested from CON (n=6) vs. MEL
(n=6) treated dams. .........................................................................................90

ix

3.20

Fetal Relative expression (mRNA abundance) of myogenin in
Longissimus dorsi, from fetuses harvested from CON (n=6) vs. MEL
(n=6) treated dams. .........................................................................................91

3.21

Fetal Relative expression (mRNA abundance) of myogenic
differentiation 1 in Longissimus dorsi, from fetuses harvested from
CON (n=6) vs. MEL (n=6) treated dams. ......................................................92

3.22

Fetal Relative expression (mRNA abundance) of CCAAT enhancer
binding protein alpha in Longissimus dorsi, from fetuses harvested
from CON (n=6) vs. MEL (n=6) treated dams. ..............................................93

3.23

Fetal Relative expression (mRNA abundance) of stearoyl-CoA
desaturase in Longissimus dorsi, from fetuses harvested from CON
(n=6) vs. MEL (n=6) treated dams. ................................................................94

3.24

Fetal Relative expression (mRNA abundance) of peroxisome
proliferator activated receptor gamma in Longissimus dorsi, from
fetuses harvested from CON (n=6) vs. MEL (n=6) treated dams. .................95

3.25

Fetal Relative expression (mRNA abundance) of patatin-like
phospholipase domain containing 2 in Longissimus dorsi, from
fetuses harvested from CON (n=6) vs. MEL (n=6) treated dams. .................96

3.26

Fetal Relative expression (mRNA abundance) of uncoupling protein 1
in perirenal adipose tissue, from fetuses harvested from CON (n=6)
vs. MEL (n=6) treated dams. ..........................................................................97

3.27

Fetal Relative expression (mRNA abundance) of adiponectin in
perirenal adipose tissue, from fetuses harvested from CON (n=6) vs.
MEL (n=6) treated dams. a-b Significance of means without common
letters (P ≤ 0.05). ............................................................................................98

3.28

Fetal Relative expression (mRNA abundance) of CCAAT enhancer
binding protein alpha in perirenal adipose tissue, from fetuses
harvested from CON (n=6) vs. MEL (n=6) treated dams. a-b
Significance of means without common letters (P ≤ 0.05) ............................99

3.29

Fetal Relative expression (mRNA abundance) of peroxisome
proliferator activated receptor gamma in perirenal adipose tissue,
from fetuses harvested from CON (n=6) vs. MEL (n=6) treated dams.
a-b
Significance of means without common letters (P ≤ 0.05) ......................100

3.30

Fetal Relative expression (mRNA abundance) of stearoyl-CoA
desaturase in perirenal adipose tissue, from fetuses harvested from
CON (n=6) vs. MEL (n=6) treated dams. a-b Significance of means
without common letters (P ≤ 0.05). ..............................................................101
x

3.31

Fetal Relative expression (mRNA abundance) of patatin-like
phospholipase domain containing 2 in perirenal adipose tissue, from
fetuses harvested from CON (n=6) vs. MEL (n=6) treated dams. ...............102

3.32

Fetal Relative expression (mRNA abundance) of insulin-like growth
factor 1 in perirenal adipose tissue, from fetuses harvested from CON
(n=6) vs. MEL (n=6) treated dams. a-b Significance of means without
common letters (P ≤ 0.05). ...........................................................................103

3.33

Fetal Relative expression (mRNA abundance) of insulin-like growth
factor 1 receptor in perirenal adipose tissue, from fetuses harvested
from CON (n=6) vs. MEL (n=6) treated dams. ............................................104

3.34

Fetal Relative expression (mRNA abundance) of insulin-like growth
factor 2 in perirenal adipose tissue, from fetuses harvested from CON
(n=6) vs. MEL (n=6) treated dams. x-y Significance of means without
common letters (P ≤ 0.05) ............................................................................105

3.35

Fetal Longissimus dorsi primary to secondary muscle fibers from
fetuses harvested from CON (n=6) vs. MEL (n=6) treated dams. ...............106

3.36

Fetal Longissimus dorsi PAX7 activated nuclei to total nuclei from
fetuses harvested from CON (n=6) vs. MEL (n=6) treated dams. x-y
Tendencies of means without common letters (P > 0.05 and P ≤ 0.10).......107

3.37

Fetal Longissimus dorsi total nuclei to total muscle fibers from
fetuses harvested from CON (n=6) vs. MEL (n=6) treated dams. ...............108

3.38

Fetal Longissimus dorsi average primary muscle fiber cross-sectional
area from fetuses harvested from CON (n=6) vs. MEL (n=6) treated
dams. .............................................................................................................109

3.39

Fetal Longissimus dorsi average secondary muscle fiber crosssectional area from fetuses harvested from CON (n=6) vs. MEL (n=6)
treated dams. .................................................................................................110

3.40

Fetal Longissimus dorsi immunohistochemistry in calves CON (n=6),
MEL (n=6). Scale bar is 200 µm in length. Image A.
immunofluorescent staining of dystrophin, C-terminal antibody (Red;
PA1-37587, Thermo Scientific, Waltham, MA). Image B.
immunofluorescent staining of BA-D5, myosin heavy chain IgG2b,
(Yellow; Developmental Studies Hybridoma Bank, University of
Iowa, Iowa City, IA). Image C. immunofluorescent staining of nuclei,
Hoescht (Blue; CAT # 33342, Thermo Scientific, Waltham, MA).
Image D. immunofluorescent staining of PAX7, hybridoma cell
supernatant (Green; Developmental Studies Hybridoma Bank). Image
E. overlays images 1 A-D. ............................................................................111
xi

4.1

Birth weight (d 0) average from offspring born from CON (n=15) or
MEL (n=12) treated dams. ...........................................................................140

4.2

Body weight (d 195) average from offspring born from CON (n=15)
or MEL (n=12) treated dams. a–b Means within a row without
common superscript differ (P < 0.05) ..........................................................141

4.3

Relative expression (mRNA abundance) of cystatin in Longissimus
dorsi from day 0 and day 195 offspring born from CON (n=15) or
MEL (n=12) treated dams. ...........................................................................142

4.4

Relative expression (mRNA abundance) of adenosine
monophosphate-activated protein kinase-α in Longissimus dorsi from
day 0 and day 195 offspring born from CON (n=15) or MEL (n=12)
treated dams. x–y Means within a row without common superscript
represent tendencies (P ≥ 0.05 and P ≤ 0.10) ...............................................143

4.5

Relative expression (mRNA abundance) of Insulin-Like Growth
factor 1 in Longissimus dorsi from day 0 and day 195 offspring born
from CON (n=15) or MEL (n=12) treated dams. x–y Means within a
row without common superscript represent tendencies (P ≥ 0.05 and
P ≤ 0.10) .......................................................................................................144

4.6

Relative expression (mRNA abundance) of Insulin-Like Growth
factor 1 receptor in Longissimus dorsi from day 0 and day 195
offspring born from CON (n=15) or MEL (n=12) treated dams. .................145

4.7

Relative expression (mRNA abundance) of Insulin-Like Growth
factor 2 in Longissimus dorsi from day 0 and day 195 offspring born
from CON (n=15) or MEL (n=12) treated dams. a–b Means within a
row without common superscript differ (P < 0.05) ......................................146

4.8

Relative expression (mRNA abundance) of Insulin-Like Growth
factor 2 receptor in Longissimus dorsi from day 0 and day 195
offspring born from CON (n=15) or MEL (n=12) treated dams. .................147

4.9

Relative expression (mRNA abundance) of myogenin in Longissimus
dorsi from day 0 and day 195 offspring born from CON (n=15) or
MEL (n=12) treated dams. ...........................................................................148

4.10

Relative expression (mRNA abundance) of myogenic differentiation
1 in Longissimus dorsi from day 0 and day 195 offspring born from
CON (n=15) or MEL (n=12) treated dams. a–b Means within a row
without common superscript differ (P < 0.05) .............................................149

xii

4.11

Relative expression (mRNA abundance) of myogenic factor 5 in
Longissimus dorsi from day 0 and day 195 offspring born from CON
(n=15) or MEL (n=12) treated dams. ...........................................................150

4.12

Relative expression (mRNA abundance) of peroxisome proliferator
activated receptor gamma in Longissimus dorsi from day 0 and day
195 offspring born from CON (n=15) or MEL (n=12) treated dams. ..........151

4.13

Relative expression (mRNA abundance) of patatin-like phospholipase
domain containing 2 in Longissimus dorsi from day 0 and day 195
offspring born from CON (n=15) or MEL (n=12) treated dams. .................152

4.14

Relative expression (mRNA abundance) of stearoyl-CoA desaturase
in Longissimus dorsi from day 0 and day 195 offspring born from
CON (n=15) or MEL (n=12) treated dams. ..................................................153

xiii

CHAPTER I
INTRODUCTION
Prenatal myogenic and adipogenic development are a large determinant of a
livestock animal’s future postnatal production potential. Changes in the uterine
environment during fetal development can alter offspring future growth potential and
result in impaired growth with increased risk of diseases (Barker, 1997, 2004, 2007;
Nathanielsz et al., 2007). This manipulation of the fetus leads to the concept of fetal
programming. Fetal programming, also known as developmental programming, is a
change in the growth and/or developmental trajectory due to a stimulus or insult during a
critical time in development for the fetus resulting in persistent effects to development
and production (Nathanielsz et al., 2007). Growth of livestock can be broken into various
phases that roughly coincide with the putative stages of production. The phases for
livestock growth consist of: conception to birth, birth to puberty, and puberty to maturity,
with harvesting of animals preceding maturity. The first critical time point in growth for
livestock is during prenatal development. The fetus at this point is completely dependent
on the dam for nutrients. These nutrients are in maternal circulation and must cross over
to the fetus through the placenta. The flux of nutrient substrates from dam to fetus is

1

dependent on the activity and accessibility of nutrient-specific transporters (Brett et al.,
2014) as well as uterine blood flow (Reynolds and Redmer, 1995). Maternal
uteroplacental blood flow increase exponentially throughout gestation in both sheep and
cattle to sustain a growing fetus (Reynolds and Redmer, 1995; Meschia, 1983). In sheep
with compromised pregnancies, both over- and undernutrition led to decreased placental
vascularity and reduced fetal weight (Chandler et al., 1985; Leury et al., 1990; Newnham
et al., 1991; Kelly, 1992; Arnold et al., 2001; Wallace et al., 2002; Redmer et al., 2004;
Luther et al., 2005; Lemley et al., 2013). In rats, decreasing placental blood flow in the
last trimester of gestation led to reduced placental weight, fetal weight, and litter size,
confirming the role of placental blood flow in fetal growth restriction (Anderson et al.,
2005). Several studies have shown that as blood flow increases throughout gestation,
nutrient transport increases (Reynolds and Redmer, 1995; Reynolds et al., 2010). This
increase in nutrient transport is not an increase in nutrient extraction per unit of blood, but
due to an increase in placental perfusion and umbilical blood flow (Reynolds et al.,
2010).
As previously mentioned, nutritional status of the dam and uteroplacental blood
flow to fetus during gestation are scenarios that can lead to developmental programming
of the offspring’s long term metabolic efficiency and productivity. Research on
nutritional effects on fetal development has shown overnutrition of dams during gestation
to increase adipogenesis and fibrogenesis in fetal skeletal muscle (Duarte et al., 2014).
Likewise, undernutrition has shown to decrease myofibril number and increase myofibril
cross-sectional area (Funston et al., 2010). These scenarios indicate that muscle and
adipose tissues are prone to manipulation during prenatal development and can be altered
1

to effect carcass quality and value. Based on these findings, providing optimal levels of
nutrition to the dam and trying to enhance uteroplacental blood flow or counter restricted
blood flow during gestation can lead to increased nutrient transport to the fetus,
supporting proper development.
Since the dam is the sole source of nutrients to the developing fetus, strategies to
maximize nutrient delivery and blood flow are needed in normal and compromised
pregnancies to ensure proper development. Therapeutic supplements such as
phosphodiesterase 5-specific inhibitors, have shown success in increasing blood flow.
The vasodilatory action of these agents occurs through the action of nitric oxide (NO)
inhibiting the breakdown of cyclic guanosine monophosphate (cGMP), resulting in
relaxation of vascular smooth muscle (Michel, 2006). However, current literature is
lacking data on the effects therapeutic blood flow supplements on uteroplacental
hemodynamics in models of rescuing fetal growth restriction. Supplementation of
melatonin (MEL) is currently being investigated as a novel approach on increasing
uteroplacental blood flow (Richter et al., 2009; Lemley et al., 2012; Brockus et al.,
2016b).
Melatonin is a natural hormone produced from the pineal gland and derived from
tryptophan acting as a vasodilator, strong antioxidant, and signaling molecule for
regulating natural circadian rhythm (Richter et al., 2009). Melatonin has also been shown
to play a significant role in promoting the recruitment of brown adipose tissue (BAT) in
newborn sheep (Seron-Ferre et al., 2015) as well as the browning of inguinal white
adipose tissue in juvenile rats (Jimenez-Aranda et al., 2013). Brown adipose is extremely
important in newborns due to its thermogenic properties. However, the fetal pineal gland
2

does not produce MEL, so all melatonin must come from maternal circulation. With the
supplementation of MEL to the dam during gestation, maternal concentrations will
increase thus increasing fetal concentrations. This increase in MEL leads to increased
blood flow of the dam, thus amount of nutrients available to the fetus and with increased
BAT recruitment can result in decreased newborn mortality (Carstens et al., 1997). A
study conducted by Brockus and colleagues (2016a) found that Holstein calves from
dams supplemented MEL during their last trimester of gestation, had significantly higher
body weights at 8 to 9 weeks of age. They hypothesized that MEL supplementation to
dams during late gestation possibly led to a response in the offspring resulting in
developmental changes in skeletal muscle (Brockus et al., 2016a).
Therefore, the objectives of this study were to determine: the effects of maternal
MEL supplementation during late gestation on the histological and molecular regulation
in the Longissimus dorsi (LM) muscle of fetal bovine offspring, composition and gene
expression of fetal perirenal (PR) adipose tissue, and LM gene expression in postnatal
offspring at birth and d 195 of age.
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CHAPTER II
LITURATURE REVIEW
2.1

Fetal Programming in Humans and Livestock
The time and prevailing environmental conditions that humans and animals are

subjected to while in utero leads to long term developmental and economic
consequences. In child health and development, fetal growth restriction resulting in low
birth weight infants’ effects on average over 350,000 infants a year in the U.S. totaling
approximately $363,000 per child in long term medical bills (Luther et al., 2005; Wallace
et al., 2006; NVSR, 2009). The effects of low birth weight not only impact the neonate’s
short-term chances of survival, it extends into adolescence and adulthood potentially
impacting their long-term quality of life. Lifelong consequences of developmental
programming can be linked to increased risk of cardiovascular disease, obesity, diabetes,
immune dysfunction, stunted growth, and more (Barker, 2004, 2007). Fetal programming
due to growth restriction is not only an issue in humans, but in livestock species as well.
In livestock, long-term health consequences resulting from a compromised uterine
environment are not as impactful due to their relatively short lifespan. Instead, livestock
animals affected by fetal programming can have dramatically altered carcass composition
which results in increased adiposity and reduced meat yield and quality. This decrease is
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production potential leads to inferior animals that take more resources to reach market.
Fetal growth restriction in livestock occurs commonly from poor nutritional environment
of the dam during gestation. Factors that influence the nutritional environment of the dam
consist of: animals that have multiple fetuses or litters; genetically selecting for greater
milk production; and the breeding of livestock during warm seasons with higher
temperatures and poor-quality forage with no supplementation (Wu et al., 2006). As
researches have witnessed with humans, fetal programming in livestock results in
increased neonatal mortality and morbidity. A larger issue with livestock is the reduced
production of affected offspring that consist of: decreased growth rate due to reduced
efficiency and ADG, poor carcass composition that contain higher amounts of adipose
tissue with reduced myofibril numbers and increased connective tissue that results in
inferior meat quality, and many diseases and other disorders (Wu et al., 2006; Reynolds
et al., 2006).
Environmental stressors such as nutrition of the dam can impact proper placental
development, leading to reduced placental vascular function and compromised fetal
growth. These stressors without maternal adaptation during gestation can reduce
uteroplacental blood flow by hampering proper vascular bed formation resulting in fetal
growth restriction or death (Vandenbosche and Kirchner, 1998; Funston et al., 2010;
Vonnahme et al., 2013). Nutrient restriction of the dam during early to mid-embryonic
development in cattle may appear to be unimportant due to size and requirements of the
fetus during this time and research has shown that 75% of fetal growth and development
occurs in the last 2 months gestation (Robinson et al., 1977). This, however, is a very
important time as maximal placental growth, differentiation, and vascularization, along
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with fetal organogenesis is occurring which lays the foundation for long-term future
development of the fetus (Funston et al., 2010). Restrictions during this phase could
reduce the size of the placenta and capacity for nutrient transfer influencing fetal growth
and development resulting in reduced birth weight and inferior growth and production
(Robinson et al., 2014). A study by Long and colleagues in 2010 found that restricting
heifers at 55% of NRC recommendations for early gestation resulted in no change to birth
weight, postnatal growth, or carcass characteristics (Long et al., 2010). However, the
offspring from this study exhibited larger myofiber cross-sectional area (Long et al.,
2010). Overall findings of early gestation nutrient restriction show a tendency for the
offspring to have reduced myofiber number due to intrauterine growth retardation
(Robinson et al., 2013).
Mid to late-gestational nutrient restriction can occur with rising nutritional
demands of the fetus. Restrictions in cattle at this point in fetal development can lead to
increased perinatal mortality, reduced birthweights, and reduced postnatal growth
(Kroker and Cummins, 1979). Fetal muscle development in cattle initially occurs within
the first 2 months post-conception, though very few muscle fibers are formed during this
time, the impact from nutrient restriction isn’t as detrimental (Russell and Oteruelo,
1981). Most of muscle cell formation occurs between 2 and 8 months of gestation with
insults to growth resulting in detrimental effects to muscle fiber number leading to
irreversible effects on meat composition throughout life (Russell and Oteruelo, 1981; Zhu
et al., 2006, Du et al., 2010). Developmental programming not only impacts yield of meat
due to reduction of muscle fiber numbers, but also negatively impacts meat quality.

9

Meat tenderness and palatability are very important to consumers, with tenderness
rated as the most important contributor to beef palatability in the United States
(Koohmaraie et al., 2002). The tenderness of meat is made up of a contribution of several
effects that include muscle fiber size and density, solubility of connective tissue (mainly
collagen), and the amount and distribution of marbling. Understanding the critical time
point in development for the muscle, adipose, and connective tissue components within
skeletal muscle and how they can be altered, is imperative for the economics of the meat
industry. Each tissue and their fetal development will be discussed in further detail
below.
2.2

Muscle Development in Cattle
In the livestock industry, animals raised for their skeletal muscle provide meat for

consumer demands. Skeletal muscle is a heterogeneous tissue made up of myocytes,
adipocytes, and fibroblasts, with the ratio of the cells determining muscle composition,
product yield, and meat quality. During fetal development, muscle accretion is
accomplished through myofiber hyperplasia and hypertrophy. This differs from postnatal
muscle accretion since the total number muscle fibers are determined before birth and
myofibers can no longer undergo hyperplasia; therefore, postnatal muscle accretion is the
result of hypertrophy of existing fibers (Du et al., 2010). The developmental foundation
for each skeletal muscle group begins with a finite pool of multipotent mesenchymal
stem cells that differentiate into mostly myocytes, with the remainder committing to
either adipocytes for intramuscular fat accumulation sites, or fibroblasts for structural
connective tissue (Dodson et al., 2010; Du et al., 2010; Yan et al., 2012). The number of
cells that commit to each of these lineages can be altered by environmental stressors such
10

as nutritional status of the dam, however, primary muscle fiber number seems to be
resistant to such influences (Dwyer et al., 1994; Zhu et al., 2006; Duarte et al., 2014).
Skeletal muscle development initiates via mesenchymal stem cells receiving signals from
neighboring tissue promoting their differentiation into myoblasts (Kollias and
McDermott, 2008; Du et al., 2010). These signals consist of Wingless and Int (Wnt) and
Sonic hedgehog which regulate the expression of paired box 3 and 7 (Pax3, Pax7). The
activation of Pax3 and Pax7 then leads to the activation of myogenic regulatory factors
such as myogenic factor 5 (Myf5), myogenic differentiation 1 (MyoD), and myogenin
(MyoG) (Buckingham, 2001; Kassar-Duchossoy et al., 2005; Du et al., 2010). Various
myogenic regulatory factors work together to promote differentiation of proliferating
myoblast into multinucleated myotubules, eventually forming mature muscle fibers
through a process known as myogenesis (Keren et al., 2006; Kollias and McDermott,
2008; Du et al., 2010). Fetal muscle development, or myogenesis, can be broken up into
two stages. First stage of myogenesis begins in early embryonic development with
myocytes proliferating into primary muscle fibers (Du et al., 2010). These primary fibers
are the foundation to which muscle groups form, acting as scaffolding for muscle fibers
to replicate. The second stage of myogenesis is responsible for the majority of myofibers
that make up skeletal muscle. This is especially important since secondary myogenesis
ends before birth, resulting in the offspring’s total muscle fiber number and future
production potential being established before birth (Stickland, 1978; Karuatatne et al.,
2005; Du et al., 2010).
In cattle, primary muscle fibers begin developing within the first 2 months and
roughly ends by 4 months post conception. Secondary muscle fibers begin forming
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between 2 to 8 months post conception (Russell and Oteruelo, 1981). Since the majority
of muscle fibers are established at this time, maternal nutritional insults during this midto late-gestational period can lead to irreversible reduction in myofiber numbers (Zhu et
al., 2006). In sheep, maternal nutrient restriction during mid- to late-gestation resulted in
reduced total secondary muscle fibers (Zhu et al., 2004). In pigs, maternal undernutrition
from days 20 to 90 of pregnancy reduced piglet birth weight and muscle fiber number
(Dwyer et al., 1994).
Another factor controlling prenatal and postnatal metabolism and muscle
development is the insulin-like growth factor signaling system (Bass et al., 1999; Holt et
al., 2012; Gonzalez et al., 2013). In this system, insulin-like growth factor 2 (IGF2) is
mainly responsible for fetal growth and muscle development as insulin-like growth factor
1 (IGF1) is mainly responsible for postnatal growth and muscle development (Florini et
al., 1991; Haig and Graham, 1991; Braxton et al., 1993; Bass et al., 1999; Le Roith et al.,
2001; Gluckman and Pinal, 2003; Gonzalez et al., 2013). Liu et al. in 1993, looked at the
effects of IGF1, IGF1 receptor (IGF1R), and IGF2 on fetal growth and development.
They found that knocking out IGF1R led to dwarfism and neonatal lethality, and that the
reduced body weight was attributed to suppressed muscle fiber hypoplasia rather than
hypertrophy in mice (Liu et al., 1993). Adams and Haddad (1996) found that rats with
increased IGF1 resulted in increased muscle mass, fiber size, and protein-to-body weight
ratio, and that IGF1 expression preceded muscle fiber hypertrophic phase.
As stated above, restricted offspring have permanent changes to muscle fiber
number and size. They develop with lower muscle fiber numbers with each fiber being
larger than normal (Foxcroft el al., 2006; Alvarenga et al., 2013). This is due to the
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inverse relationship between muscle fiber size and number (Rehfeldt and Kuhn, 2006).
This permanent reduction in muscle fiber number inhibits the potential for postnatal
catch-up of low birth weight offspring with those born without restrictions. Hypertrophy
of existing muscle fibers is the only form of postnatal muscle accretion. Reduced muscle
fiber numbers reduce meat yield and increased myofibril size that leads to reduced meat
quality (Klosowska et al., 1979; Fiedler et al., 1999). These data indicate that livestock
species in mid- to late-gestation are susceptible to fetal programming that can result in the
permanent reduction in muscle cell number and growth trajectory ultimately reducing
productivity and efficiency.
2.3

Adipose Development in Cattle
In addition to superior muscle development, producers would like to increase

intramuscular fat deposition (marbling) within skeletal muscle without wasting excessive
resources into undesirable adipose depots such as visceral, subcutaneous, and
intermuscular adipose depots. This is due to marbling contributing to the flavor and
juiciness of meat, increasing economic value as marbling increases (Crouse et al., 1983;
Hausman et al., 2009; Du et al., 2017). The extent of adipogenesis during fetal
development is critical for determining the amount of marbling that can develop
postnatally. Adipose accumulation in visceral, subcutaneous, and intermuscular depots
lowers the efficiency and economic value of livestock. This leaves researchers with the
task of selectively enhancing marbling deposition, which is the last adipose depot to
accumulate fat, while limiting formation and accretion of adipose tissue in the higher
metabolic priority, yet more undesirable depots (Crouse et al., 1983; Mir et al., 2002;
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Hausman et al., 2009; Du et al., 2017). The fetal period is an underappreciated window to
selectively impact these depots.
The total mass or volume of adipose tissue is determined by the number of
adipocytes and their respective size (Spalding et al., 2008). During the fetal stage,
adipogenesis starts with mesenchymal stem cells that can either differentiate into
myocytes, adipocytes, or fibroblasts. When mesenchymal stem cells commit to the
adipogenic lineage, starting around mid-gestation, they become future sites for adipose
tissue accretion and lipid accumulation. Permanent differentiation into adipocytes
requires self-reinforcing regulation of transcription factors CCAAT enhancer binding
protein (CEBP) and peroxisome proliferator activated receptor gamma (PPARg) (Clarke
et al., 1997; Wu et al., 1999). When CEBP alpha (CEBPA) is induced and binds to the
promoter of PPARg, it activates the expression of PPARg which further stimulates the
expression of CEBPA (Clarke et al., 1997; Wu et al., 1999). With the activation and
expression of PPARg, terminal adipogenic differentiation is achieved through the
induction of many genes that are important for triglyceride uptake and storage (Frohnert
et al., 1999; Rosen and MacDougald, 2006).
Maternal manipulation strategies can be applied during early fetal development,
to alter mesenchymal stem cell commitment into adipocytes to enhance adipogenesis
(Feve, 2005). This can result in improved intramuscular fat and meat quality; however, it
can also lead to over fattening, decreased feed efficiency, and lower retail yield. Studies
with nutrient-restricted mothers have shown adipose tissue development impaired, but
due to adipose tissue plasticity, offspring born to restricted mothers often have
compensatory gain of adipose tissue leading to fatter offspring with decreased feed
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efficiency and lower muscle mass (Zhu et al., 2006; Wang et al., 2017). The overnutrition
of pregnant ewes fed 150% of NRC requirements (NRC, 1985) has shown to increase
adipogenesis in skeletal muscle (Tong et al., 2008, 2009). This increased adiposity in
skeletal muscle can result in higher quality grades increasing the value of the carcass,
though it increases external fat as well due to intramuscular deposition being last in
priority. This increase in other fat depots lowers the yield grade of carcasses due to trim
loss resulting in a decrease in closely trimmed retail cuts. However, in cases of maternal
undernutrition, adipose tissue development is impaired, but due to adipose tissue
plasticity, offspring born to restricted mothers often have compensatory gain of adipose
tissue (Zhu et al., 2006; Wang et al., 2017). The chronological formation of adipose
depots may still hold the key to enhancing marbling while limiting overall adiposity.
Intramuscular adipocyte development primarily occurs during late gestation up to 250
days of age (Du et al., 2017). In beef cattle, providing high-energy supplementation to
early weaning calves before 250 days of age will enhance intramuscular formation
resulting in increased marbling during fattening stages (Corah and McCully, 2007; Du et
al., 2013). While postnatal feeding strategies can be used to enhance the accretion of
these depots, the initial foundation of cells and lipid accumulation within begins during
fetal development (Corah and McCully, 2007; Du et al., 2013).
In livestock, dietary energy that is above the metabolic needs of the animal is
stored as adipose tissue and can lead to obesity if left uncontrolled. Though in some
mammalian species, excessive energy storage during specific times of the year is needed
to survive. These mammals exhibit seasonal changes in adiposity that are induced either
by changes in photoperiod or an endogenous clock (Bartness et al., 2002). These seasonal
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changes effect lipid storage in white adipose tissue (WAT; the major storage of energy in
mammals) and brown adipose tissue (BAT; responsible for heat production via
thermogenesis). These environmental ques are critical for the secretion of melatonin, a
naturally produced hormone that is secreted by the pineal gland, and its role with
maintaining natural circadian rhythm.
2.4

Intramuscular Fibrogenesis in Cattle
Connective tissue not only plays a role with muscle physiology but is a major

determinant of consumer perception of meat tenderness which reported to be the single
most desirable characteristic of beef to consumers (Huffman et al., 1996). The connective
tissue that underlies this meat quality trait arises from fibroblast during early
development and begins with commitment of mesenchymal stem cells to the myogenic,
adipogenic, or firbogenic lineage (Aguiari et al., 2008; Kuang et al., 2008; YablonkaReuveni et al., 2008). These connective tissues in various types of muscles serve as
structural support by binding muscle cells together and insuring proper alignment, or to
contract providing motion (Borg and Caulfield, 1980). There are three layers of
connective tissues within skeletal muscle: epimysium surrounds the entire muscle,
perimysium is a sheath surrounding bundles of muscle fibers, and endomysium surrounds
individual muscle cells (Borg and Caulfield, 1980). These connective tissues are made up
in large part by collagen and collagen cross-links, that provides a strong and elastic
support. Connective tissue development is also influenced by growth retardation that
results in increased collagen content along with an increase in adipogenesis within fetal
skeletal muscle (Duarte et al., 2014). Studies investigating fibrogenesis in overfed ewes
and malnutrition sows have both shown that insults to the nutrient environment of the
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dam can program the fetus to have increased fibrosis which impairs muscle function and
increase meat toughness (Huang et al., 2010; Karunaratne et al., 2005).
2.5

Therapeutic Melatonin Supplementation in Normal and Compromised
Pregnancies
In compromised pregnancies, reduced uterine blood flow and placental

vascularity leads to reduced umbilical blood flow with inferior nutrient delivery resulting
in fetal growth restriction (Thureen et al., 1992; Rigano et al., 2001; Wallace et al., 2002;
Regnault et al., 2003; Kwon et al., 2004; Reynolds et al., 2005). Low birth weight
offspring born to dams with compromised pregnancies have slower growth rates,
increased chances of diseases, and increased postnatal adiposity (Barker and Clark, 1997;
Zhu et al., 2006). Therefore, studies have experimented with therapeutic treatment of
compromised pregnancies and blood flow with the use of vasodilators.
Melatonin (MEL) is a highly conserved compound that exhibits numerous
receptor mediated and receptor independent physiological effects. Melatonin is produced
by the pineal gland in the mammalian brain and in addition to its best-known effects on
circadian rhythm (Reiter, 2003), it is a powerful scavenger of free radicals (Reiter et al.,
1995; Manchester et al., 2015), involved in vasodilation (Lemley et al., 2012; Brockus et
al., 2016b), and tissue level metabolism (Ha et al., 2006; Torres-Farfan et al., 2008;
Stratos et al., 2012). Our understanding of the function of MEL begins with its discovery
and isolation by Aaron Lerner and colleagues at Yale University (Lerner et al., 1958)
who hoped to use it as a treatment for reversing the darkening effects of melanocyte
stimulating hormone on skin (Lerner et al., 1958). Melatonin was later suggested to play
a role in affecting the brain, gonads, and other neuroendocrine systems (Wurtman et al.,
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1968; Reiter et al., 1978). The pineal gland secretes melatonin during the absence of light
induced stimulus (Axelrod et al., 1964). Light is first detected by retinal ganglion cells
and transmitted via a multisynaptic pathway to the pineal gland (Larsen et al., 1998). This
neurochemical signal of photoperiod is delivered by the sympathetic nervous system
(SNS) and causes pinealocytes to secrete an endocrine signal into the bloodstream, MEL.
Light stimulus causes an interruption in the negative feedback loop needed for MEL
secretion, blocking the effects on short-day seasonal reproduction systems and seasonal
changes in adiposity (Bartness et al., 1984; Vitale et al., 1985; Moore, 1996).
The potential for MEL to prevent or rescue compromised pregnancies has gained
interest in recent years. Studies in MEL supplementation to sheep with compromised
pregnancies has shown to alter uteroplacental hemodynamics and fetal development
(Lemley et al., 2012, 2013). Likewise, in pregnant Holstein heifers, blood flow was
improved with supplemental MEL during late gestation resulting up to a 25% increase in
uterine blood flow of MEL treated heifers compared to control (Brockus et al., 2016b).
Offspring born to MEL supplemented Holstein heifers exhibited significantly greater
body weights at 8 to 9 weeks of age (Brockus et al., 2016a).
Once secreted, MEL exhibits its direct effects through binding to MEL receptors
on various tissues (Bartness et al., 2002). The known MEL receptors include MT1 and
MT2 (Dubocovich et al., 1998, 2010) and their presence has been detected on peripheral
tissues including muscle (Stratos et al., 2012) and adipose tissue (Le Gouic et al., 1997).
In skeletal muscle, binding of MEL to these receptors stimulates glucose transport into
muscle cells (Ha et al., 2006), increases the number of satellite cells, reduces
inflammation, and inhibits apoptosis by modulating associated signaling pathways
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allowing for cell regeneration (Stratos et al., 2012). Melatonin increased insulin receptor
substrate-1 is phosphorylated and the activity of phosphatidylinositol 3-kinase is
increased, resulting in increased glucose uptake (Ha et al., 2006). In adipose tissue, a
study supplementing rats with 0.4 μg/ml of MEL in water bi-weekly found a reduction in
intra-abdominal adiposity by 20%, plasma leptin (ng/ml) by 33%, and plasma insulin
(ng/ml) by 25% (Wolden-Hanson et al., 2000). Seasonal studies show a positive
correlation between increased adiposity and MEL levels (Bartness et al., 1984; Wade et
al., 1984; Bartness et al., 1985). This increase in the sympathetic drive causes an increase
in release of norepinephrine, which effects WAT and BAT. Melatonin indirectly effects
WAT through increased norepinephrine and epinephrine which results in increased
lipolysis (Youngstrom and Bartness, 1998; Demas and Bartness, 2001). Norepinephrine
stimulates increased BAT thermogenesis through cAMP-PKA signaling cascade that
causes the phosphorylation of PKA to activate hormone sensitive lipase (HSL)
(Townsend and Tseng, 2012). Hormone sensitive lipase cleaves triglycerides into free
fatty acids that are shuttled into the mitochondria to undergo β-oxidation for ATP
production or activate uncoupling protein 1 (UCP1) to produce heat via thermogenesis
(Townsend and Tseng, 2012). Thermogenesis is important for heat production in
newborns, increasing survival and homeothermy (Himms-Hagen, 1990). This links BAT
thermogenesis to newborn mortality rate, in which potentially increasing BAT
recruitment or thermogenic properties could lead to a decrease in newborn loss due to
hypothermia (Carstens et al., 1997). Studies in various species have shown MEL to
increase the amount of BAT (Jimenez-Aranda et al., 2013; Seron-Ferre et al., 2015),
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however MEL’s mechanism of action on BAT recruitment is still unknown (Bartness et
al., 2002).
Given its widespread role in central and peripheral metabolism and physiological
function, MEL has shown promise as a potential therapeutic agent to prevent or rescue
compromised pregnancies. In addition, given its role in directly modulating muscle
growth and repair as well as modulating brown and white adipose tissue metabolism,
MEL supplementation during gestation has the potential to improve the development of
these economically important tissues to improve efficiency and quality of beef
production. The underlying tissue level responses in fetal carcass tissues to maternal
MEL supplementation mechanisms have not been thoroughly investigated which is the
objective of the current research. The operational hypothesis is that maternal
supplementation of MEL during mid- to late-gestation programs the fetus for superior
postnatal development and improved skeletal muscle growth through a combination of
direct and indirect mechanisms.
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CHAPTER III
EFFECT OF MATERNAL MELATONIN SUPPLEMENTATION DURING LATE
GESTATION ON MUSCLE AND ADIPOSE TISSUE HISTOLOGY, GENE
EXPRESSION IN 240 DAY OLD BOVINE FETUSES
3.1

Abstract
Melatonin is a natural hormone that is secreted by the pineal gland and has effects

on economically important reproductive and carcass tissues including muscle and adipose
tissue. There is evidence to suggest that supplemental melatonin to dams during late
gestation may alter skeletal muscle development in fetal calves as documented by an
increased postnatal weight of calves starting at 8 weeks of age (Brockus et al., 2006a).
The objectives of this study were to determine the effects of maternal melatonin
supplementation during late gestation on the histological and molecular regulation in the
Longissimus dorsi (LM) of fetal bovine offspring and to determine the effects of
maternal melatonin on composition and gene expression of perirenal (PR) adipose tissue.
Beef heifers (n = 32) and cows (n = 25) consisting of purebred Angus, purebred
Hereford, or crossbred genetics, were bred via timed-artificial insemination and assigned
to one of two treatment groups. The treatment groups consisted of melatonin
supplementation (MEL) or without supplementation (CON). Supplementation of MEL
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was delivered via two- 24 mg implants with the CON receiving two placebo implants at
days 180, 210, and 240 of gestation. After day 240 of gestation, dams received no further
treatments and a subset of twelve crossbred heifers (n = 6 MEL; n = 6 CON) underwent
cesarean section on day 243 ± 2 of gestation to collect fetal tissue samples. Samples
consisted of LM, PR, umbilical artery and vein plasma, fetal trunk plasma, and maternal
plasma. In this study, there was no difference (P > 0.05) in fetal body weight between
calves from MEL treated dams compared to CON dams. Calves from MEL treated dams
tended to have increased LM weight and length than that of calves from CON treated
dams. Immunohistochemistry (IHC) analysis of fetal LM showed calves from dams
treated with MEL having a tendency for increased PAX7 activated nuclei to total nuclei
ratio. Relative gene expression of fetal LM identified calves from MEL treated dams to
have increased adenosine monophosphate-activated protein kinase-α (AMPK). Maternal
MEL supplementation during late gestation lead to no difference in fetal PR weight
compared to CON treated dams. However, relative gene expression of fetal PR showed
decreased adiponectin (ADIPOQ), CCAAT enhancer binding protein alpha (CEBPA),
stearoyl-CoA desaturase (SCD), peroxisome proliferator activated receptor gamma
(PPARg), insulin-like growth factor 1 (IGF1), and a tendency for decreased insulin-like
growth factor 2 (IGF2). Maternal MEL supplementation during late gestation resulted in
fetal programming of LM muscle and PR adipose tissues in the bovine offspring.
3.2

Introduction
With the rapidly increasing global population, the need for improving the

efficiency of livestock and meat production is vital. Prenatal myogenic and adipogenic
development are a large determinant of the animal’s future postnatal production potential.
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Economically important tissues such as muscle and adipose are of a lower developmental
priority compared to vital organs and nervous tissues (Zhu et al., 2006; Du et al., 2010).
This leaves muscle and adipose tissue development particularly susceptible to the
prevailing nutritional environment in utero (Zhu et al., 2006; Du et al., 2010). Stimuli
and/or insults during the development of these tissues can set the stage for increased
production efficiency, maximal growth, and superior carcasses, or lead to impaired
growth, inferior carcass composition, and increased risk of morbidity and mortality. Fetal
programming is a change in the growth trajectory due to a stimulus or insult during a
critical time in development for the fetus resulting in persisting effects into the postnatal
phases of life or production (Nathanielsz et al., 2007). The first of these critical time
points in growth for livestock is during prenatal development, at which point the fetus is
completely dependent on the dam for nutrients. Nutrients for the fetus are in maternal
circulation and must cross over to the fetus through the placenta. The nutritional status of
the dam can have long lasting effects on fetal development by permanently altering the
development of adipogenesis, fibrogenesis, and myogenesis (Karunaratne et al., 2005;
Rehfeldt and Kuhn, 2006; Zhu et al., 2006; Funston et al., 2010; Huang et al., 2010;
Duarte et al., 2014; Wang et al., 2017). However, even with sufficient nutrients in
circulation, the flux of nutrient substrates from dam to fetus is dependent on the activity
and accessibility of nutrient-specific transporters (Brett et al., 2014) as well as uterine
blood flow (Reynolds and Redmer, 1995). In humans and sheep, decrease placental blood
flow in mid- to late-gestation reduced placental weight and fetal weight (Reynolds and
Redmer, 1995; Ferrazzi et al., 2000; Konje et al., 2003; Reynolds, et al., 2005; Vonnahme
et al., 2013; Eifert et al., 2015) while decreasing litter size in rats (Anderson et al., 2005).
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The tissue level impacts in the fetus under these scenarios have not been as thoroughly
discussed.
Approaches to prevent or rescue compromised pregnancies include identifying
agents and mechanisms to improve uteroplacental nutrient exchange and in turn augment
the in utero nutritional environment experienced by the fetus. Among these,
supplementation of melatonin has been investigated as a novel therapeutic approach to
increase uteroplacental blood flow (Juaniaux et al., 2006; Paulis and Simko, 2007;
Richter et al., 2009; Lemley et al., 2012 and 2013; Vonnahme et al., 2013; Eifert et al.,
2015; Brockus et al., 2016a and 2016b). Melatonin is a natural hormone produced from
the pineal gland and derived from tryptophan. Melatonin has been described as having
pleiotropic properties acting as a vasodilator, strong antioxidant, and signaling molecule
for regulating natural circadian rhythm (Richter et al., 2009). The known melatonin
receptors include MT1 and MT2 (Dubocovich et al., 1998, 2010) and their presence has
been detected on peripheral tissues including muscle (Stratos et al., 2012) and adipose
tissue (Le Gouic et al., 1997). In skeletal muscle, binding of melatonin to these receptors
stimulates glucose transport into muscle cells (Ha et al., 2006), increases the number of
satellite cells, reduces inflammation, and inhibits apoptosis by modulating associated
signaling pathways (Stratos et al., 2012). Melatonin increased insulin receptor substrate-1
is phosphorylated and the activity of phosphatidylinositol 3-kinase is increased, resulting
in increased glucose uptake (Ha et al., 2006). Melatonin has decreased intraabdominal
adiposity in rats (Wolden-Hanson et al., 2000). Melatonin has also been shown to play a
significant role in promoting the recruitment of brown adipose tissue (BAT) in newborn
sheep (Seron-Ferre et al., 2015) as well as the browning of inguinal white adipose tissue
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(WAT) in juvenile rats (Jimenez-Aranda et al., 2013). Brown adipose is extremely
important in newborns due to its thermogenic properties which can decrease newborn
mortality (Carstens et al., 1997). Studies have found melatonin to cause increased hair
follicle growth in goats (Nixon et al.,1993), cardiovascular influence (Pechanova et
al.,2014), and decreased core body temperature in humans (Krauchi et al.,1997).
However, studies looking at similar effects in cattle are lacking. A study conducted by
Brockus et al. (2016a) supplemented Holstein heifers with melatonin to look at effects on
offspring blood pressure, heart rate, liver blood flow, skin temperature, and hair growth.
They found that calves from dams supplemented with melatonin during their last
trimester of gestation, had significantly higher body weights at 8 to 9 weeks of age
(Brockus et al., 2016a). They hypothesized that melatonin supplementation could have
altered skeletal muscle development of the calves, providing impetus for the current
study (Brockus et al., 2016a).
Therefore, our hypothesis was that increased maternal melatonin concentration
during late gestation alters the metabolic program of fetal skeletal muscle and adipose
tissue. Additionally, the increased uterine blood flow will improve postnatal growth by
programming increased myogenic mRNA gene expression in fetal skeletal muscle. The
specific objectives of this study were to determine the effects of maternal melatonin
supplementation on the histological and molecular regulation in the Longissimus dorsi
(LM) of fetal bovine offspring and to determine the effects of maternal melatonin on
composition and gene expression of perirenal (PR) adipose tissue.
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3.3
3.3.1

Materials and Methods
Animal Care and Treatment
The current study was conducted under an approved Mississippi State University

Institutional Animal Care and Use Committee protocol (#16-036).
As part of a larger study, a total of 87 heifers and 65 cows that consisted of
purebred Angus, purebred Hereford, or crossbred genetics, were bred via timed-artificial
insemination (AI) at the H. H. Leveck Animal Research Center, Mississippi State
University, MS. Heifers were bred on December 10, 2015, and cows were bred on
December 21, 2015. At d 120 post-AI, heifers and cows were examined via
ultrasonography to confirm pregnancy. This resulted in 32 heifers and 25 cows with
confirmed conception. Then dams were blocked by bodyweight and randomly assigned to
one of 2 maternal treatment groups. The 2 maternal treatment groups consist of a
melatonin treatment (MEL; n = 29) and a no melatonin treatment (CON; n = 28). The
MEL group was administered two ear impants (MelatoninImplants.com) containing 24
mg MEL each, every 30 days starting at d 180 of gestation (baseline) and ending on d
240 of gestation. The MEL implant on d 240 of gestation was expected to provide
increased maternal MEL concentration approximately till d 270 of gestation. After d 270
of gestation, all dams received no further treatments throughout the study. Furthermore,
on d 180, 210, and 240 of gestation, uterine blood flow was measured via
ultrasonography; with serum, plasma, hair scores, and thermal images also collected from
each treatment group. Both maternal treatment groups were managed the same
throughout the study and had access to similar dietary regimes with ad libitum water
access. At d 240 of gestation (~85% gestation period), 12 heifers (n = 6 CON and n = 6
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MEL) were randomly chosen to undergo Cesarean sections for collection of fetuses and
fetal tissues.
3.3.2

Cesarean Section
Cesarean surgeries were performed by veterinarians from the Mississippi State

University College of Veterinary Medicine. Once removed from the uterus, each fetal
calf was weighed, exsanguinated, and then weighed again to determine pre- and postexsanguination weights. Fetal tissue samples collected consisted of: LM, PR, and blood
for plasma and serum collection. For LM muscle samples, each sample was portioned
into two 1 cm by 1 cm samples and stored in cryotubes, tissue embedding molds, and
then stored at -80°C until further analysis. Tissue embedding consisted of a 1 cm by 1 cm
section of muscle placed in Optimal Cutting Temperature (OCT) tissue embedding
media (Fisher Scientific, Pittsburgh, PA), and frozen by submersion in supercooled
isobutane. For PR adipose samples, each sample was sectioned into 500 mg samples and
stored in cryotubes and sterile whirlpack bags, then stored at -80°C until further analysis.
Blood was collected in red and purple top tubes for collection of serum and plasma,
respectively. The samples were then spun down via centrifuge, with the supernatant layer
extracted via pipetting and portioned into cryotubes and stored at -80°C until further
analysis.
3.3.3

Analysis of Fatty Acids
Fatty acids were extracted from maternal plasma, fetal plasma, fetal umbilical

artery and vein plasma, and fetal PR adipose tissue, then esterified using a
transesterification method (O’Fallon et al., 2007). For extraction, 500 μl of plasma
38

samples and 0.1-g of PR samples were placed into a 20-ml flat bottom glass vial with
PTFE-lined silicon septum (Fischer scientific, Waltham, MA, USA). After, 200 μl (1-ml
for PR) of methyl tridecanoate (150 mg/ml in methanol; MeOH) was added as internal
standard (Sigma Aldrich, St. Louis, MO), fat was saponified in presence of 700 μl of
potassium hydroxide and 5.3-ml of methanol. Saponified FAs were then trans-esterified
in 580 μl of sulfuric acid resulting in fatty acid methyl esters (FAME). Fatty acid methyl
esters were extracted in 600 μl (3-ml for PR) of hexane, transferred into a 2-ml amber
vial, and stored in -20°C freezer until being determined by gas chromatography (GC).
For analysis, FAME were separated and quantified using a GC system (Agilent
Technologies, Santa Clara, CA) equipped with an HP- 88 capillary column (30 m × 0.25
mm, 0.2 µm film thickness; Supelco Inc., Bellefonte, PA) and a flame-ionization
detector. For carrier gas, hydrogen was used at 1.5 ml/min. Peaks were identified by
FAME standards in Supelco® 37 Component FAME Mix (Sigma-Aldrich, St. Louis,
MO), FAME #21 Mix (Restek, Bellefonte, PA), and a customized 17-component FAME
mix (Nu-Chek-Prep, Elysian, MN) and were quantified by an internal standard
calibration method. For each sample, concentrations (mg/g of adipose tissue) of FA was
converted from the corresponding FAME concentration by using molecular weight ratios
with percentages of each FA calculated by dividing its concentration (mg/g) by total FA
concentration (mg/g) and then multiplying by 100. Saturation index (SI) was calculated
by the ratio of SFA and the sum of MUFA and PUFA.
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3.3.4
3.3.4.1

Longissimus dorsi Analysis of Relative Gene Expression
QuantiNova™ SYBR® Green PCR Kit
Nucleic acids were isolated from the LM biopsy samples using 700 μl of QIAzol®

Lysis Reagent (QIAGEN, Hilden, Germany), followed by purification with the use of
RNA using a miRNeasy® Mini Kit (QIAGEN, Hilden, Germany). Extracted total RNA
was quantified using a NanoDrop One spectrophotometer (Thermo scientific, Waltham,
MA). Samples exhibiting 260 nm/280 nm ratios between 1.9 and 2.1 were deemed
acceptable for downstream procedures and stored at -80°C. For each sample, duplicate
cDNA synthesis reactions were conducted using 100 nanograms of total RNA using
QuantiNova™ Reverse Transcription Kits (QIAGEN, Hilden, Germany) according to the
manufacturers protocol. The genes of interest for LM tissue included insulin-like growth
factor 1 (IGF1), IGF1 receptor (IGF1R), insulin-like growth factor 2 (IGF2), IGF2
receptor (IGF2R), cystatin (CYS), adenosine monophosphate-activated protein kinase-α
(AMPK), lysyl oxidase (LOX), bone morphogenetic protein (BMP). Beta actin was used
as a housekeeping gene. Gene specific primers for the genes of interest (Table 3.1) were
designed and validated for quantitative PCR (qPCR). Primer efficiencies were
determined by plotting the threshold cycle versus the log of the input concentrations for
8, 10-fold serial dilutions of pooled LM muscle cDNA. Primer sets and assays with
efficiencies between 0.9 and 1.1 were considered acceptable for real time PCR analysis.
Each of the duplicate cDNA samples were subjected to duplicate qPCR reactions using
QuantiNova™ SYBR® Green PCR Kit (QIAGEN, Hilden, Germany). A master mix
containing SYBR® Green, forward and reverse primers (diluted 1:20), and ROX reference
dye along with 300 ng of cDNA was pipetted into a 96-well MicroAmp® Fast Optical
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Reaction Plate (Applied Biosystems, Foster City, CA). The plate was then covered with
Masterclear real-time PCR Film (Eppendorf, Hamburg, Germany), briefly vortexed and
centrifuged, then placed in QuantiStudio™ 3 (Applied Biosystems, Foster City, CA) for
real-time qPCR analysis. Thermal cycling parameters used consisted of: a hold stage at
95°C for 2 minutes; PCR stage with step 1 at 95°C for 5 seconds followed by step 2 at
60°C for 10 seconds for 50 cycles; with a melting curve stage have step 1 at 95°C for 1
second then step 2 60°C for 20 seconds and step 3 (dissociation) at 95°C for 1 second
(capturing every 0.1°C/s). Replicate threshold cycle (CT) values were averaged and used
for relative quantification using the 2−ΔΔCT method (Livak and Schmittgen, 2001).
3.3.4.2

TaqMan™ fast advanced master mix
Nucleic acids were isolated from the LM biopsy samples using 700 μl of

QIAzol® Lysis Reagent (QIAGEN, Hilden, Germany), followed by purification with the
use of RNA using a miRNeasy® Mini Kit (QIAGEN, Hilden, Germany). Extracted total
RNA was quantified using a NanoDrop One spectrophotometer (Thermo scientific,
Waltham, MA). Samples exhibiting 260 nm/280 nm ratios between 1.9 and 2.1 were
deemed acceptable for downstream procedures and stored at -80°C. For each sample,
duplicate cDNA synthesis reactions were conducted using 100 ng of total RNA using
QuantiNova™ Reverse Transcription Kits (QIAGEN, Hilden, Germany) according to the
manufacturer protocol. The genes of interest for LM were myogenic factor 5 (Myf5),
myogenin (MyoG), myogenic differentiation 1 (MyoD), CCAAT enhancer binding
protein alpha (CEBPA), stearoyl-CoA desaturase (SCD), peroxisome proliferator
activated receptor gamma (PPARg), and patatin-like phospholipase domain containing 2
(PNPLA2). Beta actin was used as a housekeeping gene. Assays for the genes of interest
41

(Table 3.2) were validated for efficiency and specificity prior to qPCR. Primer
efficiencies were determined by plotting the threshold cycle versus the log of the input
concentrations for 8, 10-fold serial dilutions of pooled PR adipose tissue cDNA. Primer
sets and assays with efficiencies between 0.9 and 1.1 were considered acceptable for real
time PCR analysis. Complementary DNA was amplified in duplicate using TaqMan™
fast advanced master mix (Thermo scientific, Waltham, MA). A master mix containing
TaqMan™ fast advanced master mix and gene assay was pipetted along with 100 ng of
cDNA into a 96-well MicroAmp® Fast Optical Reaction Plate (Applied Biosystems,
Foster City, CA). The plate was then covered with Masterclear real-time PCR Film
(Eppendorf, Hamburg, Germany), briefly vortexed and centrifuged, then placed in
QuantiStudio™ 3 (Applied Biosystems, Foster City, CA) for real-time qPCR analysis.
Thermal cycling parameters used consisted of: a hold stage at 50°C for 2 minutes;
polymerase activation hold at 95°C for 20 seconds; PCR stage with step 1 at 95°C for 1
second followed by step 2 at 60°C for 20 seconds for 40 cycles. Replicate CT values
were averaged and used for relative quantification using the 2−ΔΔCT method (Livak and
Schmittgen, 2001).
3.3.5

Perirenal Adipose Analysis of Relative Gene Expression
Nucleic acids were isolated from the PR biopsy samples using 700 μl of QIAzol®

Lysis Reagent (QIAGEN, Hilden, Germany), followed by purification with the use of
RNA using a miRNeasy® Mini Kit (QIAGEN, Hilden, Germany). Extracted total RNA
was quantified using a NanoDrop One spectrophotometer (Thermo scientific, Waltham,
MA). Samples exhibiting 260 nm/280 nm ratios between 1.9 and 2.1 were deemed
acceptable for downstream procedures and stored at -80°C. For each sample, duplicate
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cDNA synthesis reactions were conducted using 100 ng of total RNA using
QuantiNova™ Reverse Transcription Kits (QIAGEN, Hilden, Germany) according to the
manufacturer protocol. The genes of interest for PR adipose tissue were IGF1, IGF1R,
IGF2, IGF2R, uncoupling protein 1 (UCP1), adiponectin (ADIPOQ), CEBPA, SCD,
PPARg, and PNPLA2, with beta actin serving as housekeeping gene. Assays for the
genes of interest (Table 3.3) were validated for qPCR. Primer efficiencies were
determined by plotting the threshold cycle versus the log of the input concentrations for
8, 10-fold serial dilutions of pooled PR adipose tissue cDNA. Primer sets and assays with
efficiencies between 0.9 and 1.1 were considered acceptable for real time PCR analysis.
Complementary DNA was amplified in duplicate using TaqMan™ fast advanced master
mix (Thermo scientific, Waltham, MA). A master mix containing TaqMan™ fast
advanced master mix and gene assay was pipetted along with 100 ng of cDNA into a 96well MicroAmp® Fast Optical Reaction Plate (Applied Biosystems, Foster City, CA). The
plate was then covered with Masterclear real-time PCR Film (Eppendorf, Hamburg,
Germany), briefly vortexed and centrifuged, then placed in QuantiStudio™ 3 (Applied
Biosystems, Foster City, CA) for real-time qPCR analysis. Thermal cycling parameters
used consisted of: a hold stage at 50°C for 2 minutes; polymerase activation hold at 95°C
for 20 seconds; PCR stage with step 1 at 95°C for 1 second followed by step 2 at 60°C
for 20 seconds for 40 cycles. Replicate CT values were averaged and used for relative
quantification using the 2−ΔΔCT method (Livak and Schmittgen, 2001).
3.3.6

Analysis of Longissimus dorsi Immunohistochemistry
For each sample, the LM tissue embedded in OCT molds was sectioned into two-

10 μm cryosections via CRYOSTAR NX50 (Thermo Scientific, Waltham, MA), and
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collected on positively charged SUPERFROST™ PLUS microscope slides (Thermo
scientific, Waltham, MA). For immunodetection, nonspecific antigen binding sites were
inhibited by incubating cryosections in 100 μl of blocking solution which consisted of
5% horse serum (GE healthcare life sciences, Marlborough, MA) and 0.2% Triton-X-100
(Acros Organics, Morris, NJ) in phosphate-buffered saline (PBS) for 30 minutes. Next,
the blocking solution was removed via pipetting and cryosections were incubated with
100 μl of the following antibodies at 4°C: 1:500 Dystrophin (Thermo Scientific,
Waltham, MA), 1:10 supernatant myosin heavy chain, slow, IgG2b (BA-D5;
Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA), 1:10
hybridoma cell supernatant, IgG1 (PAX7; Developmental Studies Hybridoma Bank).
After incubating for 1 hour, then primary antibodies were removed via pipetting, and the
sections were washed 3 times for 5 minutes each with PBS. Next, the sections were
incubated with 100 μl of secondary antibodies (1:1000) for 30 minutes: Alexa Fluor 488
goat anti-mouse H&L (CAT # A-21121; Invitrogen, Carlsbad, CA), Alexa Fluor 594 goat
anti-rabbit H&L (CAT # A-11012), Alexa Fluor 633 goat anti-mouse H&L (CAT # A21146), and Hoescht (CAT # 33342; Thermo Scientific, Waltham, MA). Secondary antibodies were then removed via pipetting, and sections were washed 3 times for 5 minutes
each. A small amount of glycerol in PBS (9:1) was applied to each section and coverslipped for imaging. Cryosections were imaged and captured using an EVOS®
microscope (AMAFD1000; Life Technologies, Carlsbad, CA) with 20x magnification.
Five representative photomicrographs were captured with a minimum of 500 fibers
analyzed for each individual animal. Images captured with the EVOS® consisted of: GFP
light cube (Alexa Fluor 488), Texas Red light cube (Alexa Fluor 594), Cy5 light cube
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(Alexa Fluor 633), DAPI light cube (Hoescht 33342). Then the images were analyzed
using ImageJ (https://imagej.nih.gov/ij/download.html). Total number of primary
myofibers, secondary myofibers, primary myofiber cross-sectional area (CSA; μm2),
secondary myofiber CSA (μm2), total number of nuclei, and total number PAX7 activated
nuclei were collected and recorded. Calculations included: total primary to secondary
myofiber ratio (number of primary myofibers/number of secondary myofibers), total
PAX7 activated nuclei to total nuclei ratio (number of PAX7 nuclei/number nuclei), total
nuclei to myofiber ratio (number of nuclei/number of myofibers), average primary
myofiber CSA, and average secondary myofiber CSA.
3.3.7

Statistical Analysis
Gene expression, fatty acid analysis, immunohistochemistry, and LM

morphometrics were analyzed using MIXED procedure of the Statistical Analysis System
(SAS software version 9.4, SAS Institute, Cary, NC, USA). Where the model statement
included: treatment, fetal sex, and their respective interactions. Data found to be
nonnormally distributed were tested using the Wilcoxon rank sum test. Least square
means and standard error of the means were reported. Pairwise comparisons between the
least squares means of the treatment factor levels were computed using the PDIFF option
of the LSMEANS statement. Statistical significance was determined at P < 0.05, and Pvalues falling within P > 0.05 and P ≤ 0.10 were considered a trend.
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3.4
3.4.1

Results
Fatty Acid Analysis
Total SFA did not differ (P > 0.05) in fetal samples: umbilical artery plasma,

umbilical vein plasma, fetal trunk plasma, and PR fat from fetuses born from MEL or
CON dams (Tables 3.4-3.11; Figures 3.1-3.4). Total SFA did not differ (P > 0.05) in
maternal plasma between MEL and CON dams (Tables 3.12, 3.13; Figures 3.5).
Individual SFA did not differ (P > 0.05) in fetal samples: umbilical artery plasma,
umbilical vein plasma, fetal trunk plasma, and PR fat from fetuses born from MEL or
CON dams (Tables 3.4-3.11). Individual SFA did not differ (P > 0.05) in maternal
plasma from MEL treated dams compared to CON (Tables 3.12, 3.13).
Total MUFA did not differ (P > 0.05) in fetal samples: umbilical artery plasma,
fetal trunk plasma, and PR fat from fetuses born from MEL or CON dams (Tables 3.43.11; Figures 3.1-3.4). However, maternal MEL supplementation tended to decrease (P =
0.09) total MUFA percentage in umbilical vein plasma from fetuses born from MEL
compared to CON dams (Table 3.7). Total MUFA did not differ (P > 0.05) in maternal
plasma between MEL and CON dams (Tables 3.12, 3.13; Figures 3.5). Individual MUFA
did not differ (P > 0.05) in fetal samples: umbilical artery plasma, umbilical vein plasma,
fetal trunk plasma, and PR fat from fetuses born from MEL or CON dams (Tables 3.43.11); except for Palmitoleic acid (16:1n-7) in fetal trunk plasma, which tended to be
decreased (P = 0.07) in calves from MEL supplemented dams compared to CON (Table
3.10). Individual MUFA did not differ (P > 0.05) in maternal plasma between MEL and
CON dams (Tables 3.12, 3.13).
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Total PUFA did not differ (P > 0.05) in fetal samples: umbilical artery plasma,
umbilical vein plasma, fetal trunk plasma, and PR fat from fetuses born from MEL or
CON dams (Tables 3.4-3.11; Figures 3.1-3.4). Total PUFA did not differ (P > 0.05) in
maternal plasma between MEL and CON dams (Tables 3.12, 3.13; Figures 3.5).
Individual PUFA did not differ (P > 0.05) in fetal samples: umbilical artery plasma,
umbilical vein plasma, fetal trunk plasma, and PR fat from fetuses born from MEL or
CON dams (Tables 3.4-3.11); except for Docosahexaenoic acid (22:6) in umbilical vein
plasma and trunk plasma, which tended to be increased (P = 0.08) and (P = 0.06)
respectively, in calves from MEL supplemented dams compared to CON (Tables 3.6, 3.7,
3.11). Individual PUFA did not differ (P > 0.05) in maternal plasma between MEL and
CON dams (Tables 3.12, 3.13).
3.4.2

Fetal Morphometric Analysis
Fetal body weight did not differ (P > 0.05) between fetuses from MEL dams

compared to CON dams (Table 3.14; Figure 3.6). Fetal LM circumference and PR weight
morphometrics did not differ (P > 0.05) between fetuses from MEL dams compared to
CON dams (Table 3.14; Figures 3.8, 3.10). Fetal LM weight tended to increase (P = 0.10)
and fetal LM length tended to increase (P = 0.07) between fetuses born from MEL
compared to CON dams (Table 3.14; Figures 3.7, 3.9).
3.4.3

Fetal Longissimus dorsi Relative Gene Expression Analysis
Fetal LM relative gene expression did not differ (P > 0.05) in the following:

IGF1, IGF1R, IGF2, IGF2R, BMP, LOX, Myf5, MyoG, MyoD, CEBPA, SCD, PPARg,
or PNPLA2 between fetuses from MEL compared to CON dams (Tables 3.15, 3.16;
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Figures 3.11-3.15, 3.17, 3.19-3.25); except for CYS and AMPK, which were increased (P
= 0.02) and (P = 0.03) respectively, between fetuses born from MEL compared to CON
dams (Table 3.15; Figures 3.16, 3.18).
3.4.4

Fetal Perirenal Fat Relative Gene Expression Analysis
Fetal PR relative gene expression did not differ (P > 0.05) in UCP1, PNPLA2, or

IGF1R between fetuses from MEL compared to CON dams (Table 3.17; Figures 3.26,
3.31, 3.33). However, maternal treatment of MEL resulted in calves with decreased
relative gene expression in the following: ADIPOQ (P = 0.01), CEBPA (P = 0.03),
PPARg (P = 0.04), SCD (P = 0.02), and IGF1 (P = 0.01) compared to calves from CON
dams (Table 3.17; Figures 3.27-3.30, 3.32). Also, relative gene expression of IGF2
tended to be decreased (P = 0.09) between fetuses from MEL compared to CON dams
(Table 3.17; Figure 3.34).
3.4.5

Fetal Longissimus dorsi IHC Analysis
Fetal IHC did not differ (P > 0.05) in LM ratio of primary:secondary fibers

(Prime:Sec), number of nuclei to muscle fiber number ratio (Nuclei:Fiber), primary
muscle fiber CSA (Prime CSA), or secondary muscle fiber CSA (Sec CSA) between
fetuses born from MEL compared to CON dams (Table 3.18; Figures 3.35, 3.37-3.39);
except for the ratio of Pax7 activated nuclei to total nuclei (PAX7:Nuclei) which tended
to increase (P = 0.07) between fetuses born from MEL compared to CON dams (Table
3.18; Figure 3.36).
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3.5

Discussion
In the present study, there was no difference in fetal body weight between calves

from MEL treated dams compared to CON dams. This supports the findings of Brockus
and colleagues, as they found no difference in birth weight of Holstein calves from dams
treated with MEL or CON (2016a). The authors found this interesting as they also
reported finding a 25% increase in total uterine artery blood flow in Holstein heifers
treated with MEL compared to CON (Brockus et al., 2016b). This observed increase in
uterine artery blood flow lead them to expect an increase in birth weight of offspring, as
reduced blood flow in compromised pregnancies results in lower birth weights (Thureen
et al., 1992; Reynolds and Redmer, 1995; Ferrazzi et al., 2000; Rigano et al., 2001;
Wallace et al., 2002; Konje et al., 2003; Regnault et al., 2003; Kwon et al., 2004;
Reynolds et al., 2005; Vonnahme et al., 2013; Eifert et al., 2015). However, at weeks 8
and 9 of age, the Holstein calves from MEL treated dams had increased body weights
compared to that of calves from CON dams (Brockus et al., 2016a). The authors believed
that MEL supplementation to Holstein dams during late gestation may have caused a
programmed response leading to a change to fetal skeletal muscle development that
potentially contributed to the increased weight gain (Brockus et al., 2016a).
To investigate the effects of MEL supplementation on skeletal muscle, the entire
fetal LM muscle was collected to look at different morphometric measurements
consisting of weight, circumference, and length. Maternal supplementation of MEL
during late gestation resulted in fetal LM tending to weigh more and be longer than that
of calves from CON treated dams. Upon IHC analysis, fetal LM of calves from dams
treated with MEL had a tendency for increased PAX7 activated nuclei to total nuclei
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ratio. The activation of PAX7 is required for fetal myoblast formation as PAX7+
progenitor cells act as a foundation and give rise to myogenic cells necessary for fetal
skeletal muscle accretion (Hutcheson et al., 2009). This tendency for increased PAX7
activation in fetal LM may explain the observed tendency for increased LM weight and
length. To investigate further, fetal LM tissue was also collected for relative gene
expression of genes responsible for myogenesis, adipogenesis, and fibrogenesis, as well
as genes responsible for muscle metabolism.
Skeletal muscle is a heterogenous tissue comprised of myocytes, adipocyte, and
fibrocytes with the overall ratio and distribution of these cells determining muscle
composition, product yield, and meat quality. This lead to our decision to not only look at
genes responsible for myogenesis, but adipogenic and fibrogenic genes as well (Tables
3.1-3.3). Maternal supplementation of MEL during late gestation led to no difference in
the examined myogenic and adipogenic genes. However, MEL supplementation lead to
calves with increased CYS relative gene expression. A study conducted by Gonzalez et
al. (2013) with nutrient restricting cross-bred cows from day 30 of gestation till day 85 of
gestation resulted in fetuses with a tendency for CYS to be increased compared to fetuses
from non-restricted dams. They concluded that the increase would result in increased
numbers of connective tissue fibroblasts (Gonzalez et al., 2013)
Muscle accretion is not only influenced by myogenic genes, but also genes that
influence muscle metabolism which provides the necessary energy for muscle growth.
Maternal supplementation of MEL during late gestation led to an increase in AMPK
relative gene expression in fetal LM compared to that of calves from CON dams.
Increased AMPK activity has been shown to increase glucose uptake, fatty acid
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oxidation, and mitochondrial biogenesis by increasing the expression of genes
responsible for these metabolic pathways (Jager et al., 2007). The ability for AMPK to
increase glucose uptake is very important as skeletal muscle is responsible for 65% of
fetal glucose disposal (Hay, 2003). In an AMPK knockout study using mice, researchers
found that AMPK modulates several metabolic genes within muscle tissue and could be a
candidate for transmitting exercise signals to the nucleus (Jorgensen et al., 2006).
Therefore, the increased AMPK expression could potentially lead to increased glucose
uptake and cell recovery in skeletal muscle in cattle and decrease triglycerides within
skeletal muscle resulting in leaner beef.
In addition to investigating the effects of MEL on skeletal muscle, we also looked
at blood plasma and PR adipose tissue. The effects of MEL on decreasing adiposity is
well documented in rodents (Elliott et al., 1989; Puchalski et al., 2003; Raskind et al.,
2007; Korhonen et al., 2008). Maternal supplementation of MEL during late gestation
resulted in no difference in fetal PR weight of calves between treatment groups. This is
surprising as studies with sheep (Seron-Ferre et al., 2015) and hamsters (Heldmaier and
Hoffmann, 1974) have shown MEL to increase BAT growth. The absence of BAT
accretion in the calves may potentially be due to MEL decreasing relative gene
expression of adipogenic genes: ADIPOQ, CEBPA, PPARg, and SCD.
Studies on the effects of ADIPOQ have shown increased ADIPOQ expression to reduce
plasma glucose, reverse insulin resistance, and decrease triglyceride content of adipose
tissue (Yamauchi et al., 2001; Nishizawa et al., 2002; Diez and Iglesias, 2003). Yamauchi
et al. (2001) suggested that ADIPOQ may be partially regulated by PPARg due to their
findings of no detectable ADIPOQ expression in adipose depleted mice which was
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achieved by a severe reduction in PPARg activity. Stimulation of PPARg not only
mediates adipose accretion, but adipogenesis during fetal development. Permanent
differentiation of mesenchymal stem cells into adipocytes requires self-reinforcing
regulation of transcription factors CEBPA and PPARg (Clarke et al., 1997; Wu et al.,
1999). When CEBPA is induced and binds to the promoter of PPARg, it activates the
expression of PPARg which further stimulates the expression of CEBPA (Clarke et al.,
1997; Wu et al., 1999). With the activation and expression of PPARg, terminal
adipogenic differentiation is achieved through the induction of many genes that are
important for triglyceride uptake and storage (Frohnert et al., 1999; Rosen and
MacDougald, 2006). Decreased expression of CEBPA and PPARg causes decrease fat
deposition (Tontonoz et al., 1994; Forman et al., 1995; Barak et al., 1999; Lan et al.,
2013), with CEBPA also being attributed as a regulator for BAT differentiation
(Armengol et al., 2012). The stimulation of SCD plays an important role in adipose
development through mediating MUFA synthesis, as it is the rate-limiting enzyme for
biosynthesis (Ntambi et al., 2002). Mice with SCD knocked out have shown to exhibit
reduced triglyceride synthesis and storage, resulting in decreased adiposity and mice had
increased insulin sensitivity (Ntambi et al., 2002).
After observing decreases in genes responsible for adipogenic gene express in PR
adipose tissue and the increase of metabolic gene AMPK in LM muscle tissue, we
decided to look at metabolic genes in PR adipose tissue as well. Maternal
supplementation of MEL during late gestation resulted in decreased IGF1 relative gene
expression and tended to decrease IGF2 in PR adipose tissue. The effects of IGF2 is
mainly responsible for fetal growth and IGF1 is mainly responsible for postnatal growth
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and development (Florini et al., 1991; Haig and Graham, 1991; Braxton et al., 1993; Bass
et al., 1999; Le Roith et al., 2001; Gluckman and Pinal, 2003; Gonzalez et al., 2013). The
stimulation of IGF1 has shown to play an important role in adipogenesis by increasing
the recruitment of cells thereby increasing adipose cell numbers (Hu et al., 2015), while
IGF2 has been suggested to play a role in preventing terminal adipocyte differentiation
(Gardan et al., 2008; Kleiman et al., 2013).
In Summary, maternal supplementation of MEL during late gestation does impact
LM muscle and PR adipose tissue development of fetal calves by d 240 of gestation. The
increase in metabolic associated genes within the LM promoting lipid oxidation and
energy uptake paired with the decreased adipogenic gene expression could lead to calves
with less adiposity and improved muscle accretion. Future analysis of fetal PR adipose
morphology via IHC will be needed to determine the extent of physical changes to size
and/or number of adipocytes. Also, further research into the effects of maternal
supplementation of MEL during late gestation on postnatal calves will be needed to
determine long term implications.
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Table 3.1

Gene1

Accession

IGF2

NM_001077828.
1
NM_001244612.
1
HQ703509.1

IGF2R

NM_174352.2

BMP

XM_001788198.
2

CYS

NM_174029.1

LOX

NM_173932.4

AMPK

NM_001109802

Beta
Actin

NM_173979

IGF1
IGF1R

1

Accession, sequences, amplicon length, and efficiency of primers used for
QuantiNovaTM SYBR® Green real-time PCR quantification of Longissimus
dorsi gene expression.
Amplicon
Size

Forward Primer

Reverse Primer

TTGGTGGATGCTCTCCAGTTC

AGCAGCACTCATCCACGATTC

AAGAACCATGCCTGCAGAAG
G
GACCGCGGCTTCTACTTCAG
GATGAAGGAGGCTGCAAGGA
T
CAGAGGAAGGGCTTCCAGGC
A
GTGGAGCTTGGCCGGACTACA
T
GGCTTGAGTCCTGGCTGCTAT
GA
ACCATTCTTGGTTGCTGAAAC
TC

GGATTCTCAGGTTCTGGCCAT
T
AAGAACTTGCCCACGGGGTAT
CCTGATGCCTGTAGTCCAGCT
T

GTCGACACCGCAACCAGTT

Efficiency

117

1.02

104

1.05

202

0.97

99

0.95

GGAACACCAGCTCCACACCAT

177

0.96

CACCAGGTTGATGGTGTTCAT
CC

143

1.04

GTGCAGCCCGAGGCATATGCG

202

0.99

CACCTTGGTGTTTGGATTTCTG

80

0.99

AAGCCGGCCTTGCACAT

85

0.94

IGF1 = insulin-like growth factor 1, IGF1R = IGF1 receptor, IGF2 = insulin-like growth
factor 2, IGF2R = IGF2 receptor, BMP = bone morphogenetic protein, CYS = cystatin,
LOX = lysyl oxidase, AMPK = adenosine monophosphate-activated protein kinase-α
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Table 3.2

Assays, accession, amplicon length, and efficiency of primers used for
TaqMan® real-time PCR quantification of Longissimus dorsi gene
expression.

Gene1
Assay ID
Accession
Amplicon Size Efficiency
Beta Actin Bt03279174_g1
NP_776404
141
0.96
Myf5
Bt03223134_m1
NP_776541
98
0.95
MyoG
Bt03258928_m1
NP_001104795.1
96
0.96
MyoD
Bt03244740_m1
NP_001035568.2
84
0.95
CEBPA
Bt03224529_s1
NP_789741
124
0.99
SCD
Bt04307478_m1
NP_776384.3
89
0.97
PPARg
Bt03217547_m1
NP_851367.1
85
0.93
PNPLA2
Bt03234128_m1
NP_001039470.1
77
0.98
1
Myf5 = myogenic factor 5, MyoG = myogenin, MyoD = myogenic differentiation 1,
CEBPA = CCAAT enhancer binding protein alpha, SCD = stearoyl-CoA desaturase,
PPARg = peroxisome proliferator activated receptor gamma, PNPLA2 = patatin-like
phospholipase domain containing 2.
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Table 3.3

Assays, accession, amplicon length, and efficiency of primers used for
TaqMan® real-time PCR quantification of perirenal adipose tissue gene
expression.

Gene1
Assay ID
Accession
Amplicon Size Efficiency
Beta Actin Bt03279174_g1
NP_776404
141
0.97
UCP1
Bt04301238_m1
NM_001166528.1
74
0.92
ADIPOQ Bt03292341_s1
NM_174742.2
121
0.94
CEBPA
Bt03224529_s1
NP_789741
124
0.92
PPARG
Bt03272016_m1
NM_001101152.2
65
0.94
SCD
Bt04307478_m1
NP_776384.3
89
0.95
PNPLA2
Bt03234128_m1
NP_001039470.1
77
0.99
IGF2
Bt03259225_m1
NP_776512.2
54
0.95
IGF1
Bt03252282_m1
NM_001077828.1
65
0.99
IGF1R
Bt03649217_m1
NP_001231541.1
70
0.93
1
UCP1 = uncoupling protein 1, ADIPOQ = adiponectin, CEBPA = CCAAT
enhancer binding protein alpha, PPARg = peroxisome proliferator activated
receptor gamma, SCD = stearoyl-CoA desaturase, PNPLA2 = patatin-like
phospholipase domain containing 2, IGF2 = insulin-like growth factor 2, IGF1 =
insulin-like growth factor 1, IGF1R = IGF1 receptor.
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Table 3.4

Fetal umbilical artery composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA) of calves CON (n=6),
MEL (n=6).

Fetal Umbilical Artery (mg/ml)
Treatment
Fatty Acid
CON
MEL
SEM
P Value
0.52
SFA
0.2812
0.2665
0.0221
15:0
0.30
0.0096
0.0077
0.0017
16:0
0.62
0.1696
0.1628
0.0133
17:0
0.32
0.0118
0.0082
0.0035
18:0
0.80
0.0900
0.0883
0.0065
0.57
MUFA
0.1818
0.1727
0.0153
14:1n-5
0.48
0.0062
0.0035
0.0037
16:1n-7
0.44
0.0306
0.0285
0.0026
17:1n-8
0.43
0.0096
0.0078
0.0021
18:1n-trans
0.30
0.0010
0.0000
0.0009
18:1n-9 cis
0.92
0.1342
0.1330
0.0121
0.45
PUFA
0.1044
0.0940
0.0131
18:2n-6
0.83
0.0474
0.0467
0.0033
18:3n-3
0.98
0.0142
0.0143
0.0051
20:3n-6
0.11
0.0106
0.0070
0.0020
20:4n-6
0.54
0.0248
0.0217
0.0049
20:5n-3
0.44
0.0062
0.0047
0.0019
22:6
0.30
0.0012
0.0000
0.0011
0.48
TOTAL
0.5676
0.5333
0.0462
*
0.65
SI
0.9860
1.0067
0.0434
**
0.38
DI
0.3880
0.3933
0.0058
*
SI = saturation index (total SFA/total MUFA + total PUFA)
**
DI = desaturation index (16:1n-7 + 18:1n-9 cis/16:0 + 16:1n-7 + 18:0 + 18:1n-9 cis)
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Table 3.5

Fetal umbilical artery composition in percent of saturated (SFA),
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA) of
calves CON (n=6), MEL (n=6).

Fetal Umbilical Artery1 (%)
Treatment
Fatty Acid
CON
MEL
SEM
SFA
49.5600
50.1083
1.0867
15:0
1.6380
1.4100
0.2492
16:0
29.9420
30.5733
0.5802
17:0
2.0180
1.5550
0.5655
18:0
15.9660
16.5717
0.7104
MUFA
32.0600
32.3733
0.7948
14:1n-5
1.0880
0.5900
0.6531
16:1n-7
5.3740
5.3750
0.1825
17:1n-8
1.6580
1.4683
0.2987
18:1n-trans
0.2220
0.0000
0.2004
18:1n-9 cis
23.7140
24.9383
1.0539
PUFA
18.3780
17.5183
1.6326
18:2n-6
8.3640
8.7633
0.4156
18:3n-3
2.4280
2.5850
0.8981
20:3n-6
1.8860
1.2967
0.3636
20:4n-6
4.3240
3.9933
0.7190
20:5n-3
1.1780
0.8767
0.3998
22:6
0.2000
0.0000
0.1805
1
Fatty acid normalized percentages to total fatty acids
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P Value
0.63
0.38
0.30
0.43
0.42
0.70
0.47
1.00
0.54
0.30
0.28
0.61
0.36
0.87
0.14
0.66
0.47
0.30

Table 3.6

Fetal umbilical vein composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA) of calves CON (n=6),
MEL (n=6).

Fetal Umbilical Vein (mg/ml)
Treatment
Fatty Acid
CON
MEL
SEM
P Value
0.68
SFA
0.2783
0.2872
0.0207
15:0
0.16
0.0070
0.0127
0.0036
16:0
0.87
0.1680
0.1698
0.0112
17:0
0.28
0.0070
0.0113
0.0037
18:0
0.75
0.0963
0.0935
0.0087
0.80
MUFA
0.1990
0.1933
0.0214
14:1n-5
1.00
0.0020
0.0020
0.0013
16:1n-7
0.94
0.0283
0.0282
0.0023
17:1n-8
0.59
0.0090
0.0110
0.0036
18:1n-trans
0.87
0.0260
0.0303
0.0265
18:1n-9 cis
0.62
0.1340
0.1217
0.0237
0.14
PUFA
0.0967
0.1357
0.0235
18:2n-6
0.26
0.0453
0.0480
0.0022
18:3n-3
0.25
0.0157
0.0165
0.0007
20:3n-6
0.86
0.0077
0.0080
0.0018
20:4n-6
0.92
0.0237
0.0232
0.0050
20:5n-3
0.91
0.0040
0.0042
0.0015
x
y
22:6
0.08
0.0000
0.0362
0.0176
0.47
TOTAL
0.5743
0.6165
0.0548
*
0.38
SI
0.9500
0.8850
0.0696
**
0.64
DI
0.3767
0.3617
0.0307
x–y
Means within a row without common superscript represent tendencies (P ≥ 0.05 and P
≤ 0.10)
*
SI = saturation index (total SFA/total MUFA + total PUFA)
**
DI = desaturation index (16:1n-7 + 18:1n-9 cis/16:0 + 16:1n-7 + 18:0 + 18:1n-9 cis)
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Table 3.7

Fetal umbilical vein composition in percent of saturated (SFA),
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA) of
calves CON (n=6), MEL (n=6).

Fetal Umbilical Vein1 (%)
Treatment
Fatty Acid
CON
MEL
SEM
P Value
SFA
48.6700
46.7883
1.8450
0.34
15:0
1.2367
2.0233
0.5595
0.20
16:0
29.4500
27.6833
1.4001
0.25
17:0
1.2067
1.8033
0.5462
0.31
18:0
16.7700
15.2817
0.9339
0.16
x
y
MUFA
34.4033
31.4650
1.5222
0.09
14:1n-5
0.2833
0.3417
0.2025
0.78
16:1n-7
4.9800
4.6067
0.3386
0.31
17:1n-8
1.5133
1.7700
0.5536
0.66
18:1n-trans
4.1933
4.7467
4.1065
0.90
18:1n-9 cis
23.4300
19.9983
3.8784
0.41
PUFA
16.9233
21.7467
2.8208
0.13
18:2n-6
8.0867
7.8067
0.6111
0.66
18:3n-3
2.8300
2.6983
0.2931
0.67
20:3n-6
1.3467
1.2933
0.2404
0.83
20:4n-6
3.9433
3.7133
0.5807
0.70
20:5n-3
0.7167
0.6700
0.2422
0.85
x
y
22:6
0.0000
5.5667
2.6797
0.08
x–y
Means within a row without common superscript represent tendencies (P ≥ 0.05 and P
≤ 0.10)
1
Fatty acid normalized percentages to total fatty acids
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Table 3.8

Fetal perirenal fat composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA) of calves CON (n=6),
MEL (n=6).

Fetal Perirenal fat (mg/ml)
Treatment
Fatty Acid
CON
MEL
SEM
P Value
0.77
SFA
285.4800
278.6900
22.1971
8:0
0.35
0.1760
0.1464
0.0301
10:0
0.20
0.4026
0.3177
0.0615
12:0
0.39
0.4292
0.3540
0.0835
14:0
0.65
16.6552
15.1861
3.1679
15:0
0.66
0.2430
0.2334
0.0211
16:0
0.92
203.4000
201.9400
14.8767
18:0
0.55
64.1806
60.5114
5.9566
0.27
MUFA
265.8800
280.2300
12.1603
14:1n-5
0.73
5.1440
5.4031
0.7405
16:1n-7
0.83
40.2998
39.5599
3.3678
17:1n-8
0.79
1.4928
1.5276
0.1284
18:1n-trans
0.26
1.0998
1.1584
0.0493
18:1n-9 cis
0.27
215.5100
230.1100
12.3752
20:1n-9
0.56
2.0660
2.2594
0.3186
24:1n-9
0.27
0.2640
0.2110
0.0456
0.53
PUFA
4.7594
4.4243
0.5140
18:2n-6
0.50
1.8620
1.7579
0.1472
18:3n-6
0.33
0.0852
0.0720
0.0128
18:3n-3
0.55
0.8818
0.9223
0.0651
20:2
0.76
0.1144
0.1237
0.0292
20:3n-6
0.42
0.3958
0.3194
0.0899
20:4n-6
0.33
0.9070
0.7610
0.1433
20:5n-3
0.23
0.0876
0.1176
0.0233
22:6
0.47
0.4256
0.3507
0.0991
0.76
TOTAL
556.1200
563.3500
23.2497
*
0.51
SI
1.0588
0.9879
0.1031
**
0.48
DI
0.4902
0.5074
0.0235
*
SI = saturation index (total SFA/total MUFA + total PUFA)
**
DI = desaturation index (16:1n-7 + 18:1n-9 cis/16:0 + 16:1n-7 + 18:0 + 18:1n-9 cis)
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Table 3.9

Fetal perirenal fat composition in percent of saturated (SFA),
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA) of
calves CON (n=6), MEL (n=6).

Fetal Perirenal fat1 (%)
Treatment
Fatty Acid
CON
MEL
SEM
SFA
51.1814
49.3514
2.4252
8:0
0.0314
0.0260
0.0055
10:0
0.0716
0.0566
0.0101
12:0
0.0764
0.0627
0.0137
14:0
2.9674
2.6827
0.4982
15:0
0.0432
0.0417
0.0034
16:0
36.4966
35.7701
1.5633
18:0
11.4946
10.7116
0.7826
MUFA
47.9658
49.8613
2.4136
14:1n-5
0.9236
0.9616
0.1248
16:1n-7
7.2716
7.0387
0.6347
17:1n-8
0.2674
0.2726
0.0220
18:1n-trans
0.1978
0.2064
0.0092
18:1n-9 cis
38.8826
40.9404
2.3259
20:1n-9
0.3744
0.4039
0.0628
24:1n-9
0.0480
0.0374
0.0087
PUFA
0.8528
0.7873
0.0850
18:2n-6
0.3338
0.3134
0.0241
18:3n-6
0.0154
0.0127
0.0022
18:3n-3
0.1588
0.1641
0.0123
20:2
0.0204
0.0219
0.0048
20:3n-6
0.0704
0.0566
0.0152
20:4n-6
0.1622
0.1351
0.0244
20:5n-3
0.0158
0.0211
0.0044
22:6
0.0760
0.0621
0.0170
1
Fatty acid normalized percentages to total fatty acids
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P Value
0.47
0.35
0.17
0.34
0.58
0.67
0.65
0.34
0.45
0.77
0.72
0.82
0.37
0.40
0.65
0.25
0.46
0.42
0.25
0.67
0.77
0.38
0.29
0.25
0.44

Table 3.10

Fetal trunk plasma composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA) of calves CON (n=6),
MEL (n=6).

Fetal Plasma (mg/ml)
Treatment
Fatty Acid
CON
MEL
SEM
P Value
0.27
SFA
0.3564
0.2479
0.0920
15:0
0.70
0.0090
0.0074
0.0039
16:0
0.23
0.1892
0.1497
0.0308
17:0
0.28
0.0088
0.0044
0.0038
18:0
0.27
0.1498
0.0863
0.0543
0.22
MUFA
0.2170
0.1573
0.0452
14:1n-5
0.26
0.0006
0.0000
0.0005
x
y
16:1n-7
0.07
0.0294
0.0241
0.0026
17:1n-8
0.36
0.0084
0.0063
0.0022
18:1n-trans
0.26
0.0120
0.0001
0.0099
18:1n-9 cis
0.22
0.1662
0.1264
0.0303
0.26
PUFA
0.1818
0.0840
0.0816
18:2n-6
0.26
0.1216
0.0447
0.0641
18:3n-3
0.26
0.0014
0.0000
0.0012
20:3n-6
0.29
0.0116
0.0067
0.0044
20:4n-6
0.20
0.0294
0.0184
0.0080
20:5n-3
0.34
0.0096
0.0039
0.0057
22:6
0.27
0.0084
0.0106
0.0018
0.25
TOTAL
0.7554
0.4894
0.2184
*
0.14
SI
0.9600
1.0286
0.0430
0.60
DI**
0.3800
0.3871
0.0130
x–y
Means within a row without common superscript represent tendencies (P ≥ 0.05 and P
≤ 0.10)
*
SI = saturation index (total SFA/total MUFA + total PUFA)
**
DI = desaturation index (16:1n-7 + 18:1n-9 cis/16:0 + 16:1n-7 + 18:0 + 18:1n-9 cis)
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Table 3.11

Fetal trunk plasma composition in percent of saturated (SFA),
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA) of
calves CON (n=6), MEL (n=6).

Fetal Plasma1 (%)
Treatment
Fatty Acid
CON
MEL
SEM
P Value
SFA
48.8320
50.6714
1.1309
0.13
15:0
1.0620
1.4929
0.3533
0.25
16:0
28.5280
30.5771
2.1035
0.35
17:0
0.9900
0.9314
0.1355
0.67
18:0
18.2540
17.6700
1.0046
0.57
MUFA
31.2480
32.1543
1.5655
0.58
14:1n-5
0.0480
0.0071
0.0279
0.17
16:1n-7
4.7780
4.9614
0.5412
0.74
17:1n-8
1.2060
1.2829
0.1597
0.64
18:1n-trans
0.6680
0.0343
0.5543
0.28
18:1n-9 cis
24.5440
25.8657
1.5711
0.42
PUFA
19.9180
17.1771
2.5486
0.31
18:2n-6
11.9920
9.1643
2.4893
0.28
18:3n-3
0.2560
0.0000
0.2120
0.26
20:3n-6
1.4100
1.3271
0.1756
0.65
20:4n-6
3.9900
3.7629
0.4484
0.62
20:5n-3
0.8860
0.7786
0.2673
0.70
x
y
22:6
1.3820
2.1400
0.3517
0.06
x–y
Means within a row without common superscript represent tendencies (P ≥ 0.05 and P
≤ 0.10)
1
Fatty acid normalized percentages to total fatty acids

64

Table 3.12

Maternal plasma composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA) of calves CON (n=6),
MEL (n=6).

Maternal Plasma (mg/ml)
Treatment
Fatty Acid
CON
MEL
SEM
P Value
0.97
SFA
0.5550
0.5570
0.0581
15:0
0.38
0.0196
0.0179
0.0019
16:0
0.83
0.2514
0.2473
0.0188
17:0
0.74
0.0182
0.0174
0.0023
18:0
0.83
0.2664
0.2746
0.0361
0.87
MUFA
0.3140
0.3093
0.0273
14:1n-5
0.83
0.0186
0.0181
0.0021
16:1n-7
0.59
0.0314
0.0300
0.0025
17:1n-8
0.86
0.0110
0.0107
0.0016
18:1n-trans
0.86
0.0372
0.0386
0.0077
18:1n-9 cis
0.85
0.2160
0.2123
0.0186
0.49
PUFA
0.5496
0.5140
0.0500
18:2n-6
0.54
0.3038
0.2840
0.0313
18:3n-3
0.71
0.1486
0.1429
0.0148
20:3n-6
0.16
0.0246
0.0206
0.0027
20:4n-6
0.22
0.0468
0.0389
0.0061
20:5n-3
0.86
0.0242
0.0239
0.0018
22:6
0.16
0.0016
0.0040
0.0016
0.77
TOTAL
1.4186
1.3803
0.1278
*
0.37
SI
0.6420
0.6743
0.0345
**
0.49
DI
0.3280
0.3186
0.0133
*
SI = saturation index (total SFA/total MUFA + total PUFA)
**
DI = desaturation index (16:1n-7 + 18:1n-9 cis/16:0 + 16:1n-7 + 18:0 + 18:1n-9 cis)
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Table 3.13

Maternal plasma composition in percent of saturated (SFA),
monounsaturated (MUFA), and polyunsaturated fatty acids (PUFA) of
calves CON (n=6), MEL (n=6).

Maternal Plasma1 (%)
Treatment
Fatty Acid
CON
MEL
SEM
SFA
39.0940
40.2229
1.1765
15:0
1.3820
1.2843
0.0933
16:0
17.8360
17.9429
0.4434
17:0
1.2640
1.2600
0.0868
18:0
18.6100
19.7329
1.0756
MUFA
22.2260
22.4186
0.7255
14:1n-5
1.3320
1.3014
0.1170
16:1n-7
2.2240
2.1986
0.1545
17:1n-8
0.7720
0.7643
0.0962
18:1n-trans
2.5680
2.7400
0.4035
18:1n-9 cis
15.3300
15.4186
0.7042
PUFA
38.6820
37.3600
1.2863
18:2n-6
21.3200
20.5829
0.8042
18:3n-3
10.4720
10.4300
0.7707
20:3n-6
1.7560
1.4914
0.1574
20:4n-6
3.3240
2.8043
0.3413
20:5n-3
1.7020
1.7600
0.1520
22:6
0.1080
0.2900
0.1134
1
Fatty acid normalized percentages to total fatty acids
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P Value
0.36
0.32
0.81
0.96
0.32
0.80
0.80
0.87
0.94
0.68
0.90
0.33
0.38
0.96
0.12
0.16
0.71
0.14

Table 3.14

Fetal morphometrics with body weight (BW; kg) and Longissimus dorsi
(LM) weight (kg), circumference (cm), and length (cm) of muscle and
perirenal (PR) adipose tissue weight (kg) for calves CON (n=6), MEL
(n=6).

Morphometric Measurements
Treatment
Measurements
CON
MEL
SEM
P Value
BW (kg)
24.0000
22.9000
1.9000
0.56
x
y
LM Weight (kg)
0.2218
0.2633
0.0227
0.10
LM Circumference (cm)
32.8833
38.5667
4.1250
0.21
LM Length (cm)
10.0667x
11.4500y
0.6564
0.07
PR Weight (kg)
0.0623
0.1667
0.0984
0.32
x–y
Means within a row without common superscript represent tendencies (P ≥ 0.05 and P
≤ 0.10)
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Table 3.15

QuantiNovaTM SYBR® Green real-time PCR quantification of Fetal
Longissimus dorsi (LM) PCR relative expression of IGF1, IGF1R, IGF2,
IGF2R, BMP, CYS, LOX, and AMPK of calves CON (n=6), MEL (n=6).

Longissimus dorsi PCR Relative Expression
Treatment
1
Gene
CON
MEL
SEM
P Value
IGF1
5.3333
7.6667
1.7847
0.23
IGF1R
5.5000
7.5000
1.8359
0.31
IGF2
5.5000
7.5000
1.5753
0.24
IGF2R
5.6667
7.3333
1.6777
0.35
BMP
5.6667
7.3333
1.8053
0.38
CYS
4.3333a
8.6667b
1.4985
0.02
LOX
5.5000
7.5000
1.7213
0.28
a
b
AMPK
0.03
4.5000
8.5000
1.5516
a–b
Means within a row without common superscript differ (P < 0.05)
1
IGF1 = insulin-like growth factor 1, IGF1R = IGF1 receptor, IGF2 = insulin-like growth
factor 2, IGF2R = IGF2 receptor, CYS = cystatin, AMPK = adenosine monophosphateactivated protein kinase-α, LOX = lysyl oxidase, BMP = bone morphogenetic protein
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Table 3.16

TaqMan® real-time PCR quantification of Fetal Longissimus dorsi (LM)
PCR relative expression of IGF1, IGF1R, IGF2, IGF2R, BMP, CYS, LOX,
and AMPK of calves CON (n=6), MEL (n=6).

LM PCR Relative Expression
Treatment
1
Gene
CON
MEL
SEM
P Value
Myf5
6.4167
6.5833
1.9003
0.93
MyoG
5.2500
7.7500
1.6429
0.17
MyoD
6.0000
7.0000
1.7717
0.59
CEBPA
5.2500
7.7500
1.8130
0.21
SCD
5.8333
7.1667
1.9245
0.51
PPARg
6.1667
6.8333
1.5986
0.69
PNPLA2
5.4167
7.5833
1.6073
0.21
1
Myf5 = myogenic factor 5, MyoG = myogenin, MyoD = myogenic differentiation 1,
CEBPA = CCAAT enhancer binding protein alpha, SCD = stearoyl-CoA desaturase,
PPARg = peroxisome proliferator activated receptor gamma, PNPLA2 = patatin-like
phospholipase domain containing 2.
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Table 3.17

Fetal perirenal adipose tissue (PR) PCR relative expression of ADIPOQ,
IGF1, and UCP1 of calves CON (n=6), MEL (n=6).

PR PCR Relative Expression
Treatment
1
Gene
CON
MEL
SEM
P Value
UCP1
7.0000
6.0000
1.9484
0.62
ADIPOQ
8.8333a
4.1667b
1.3878
0.01
a
b
CEBPA
8.1667
4.8333
1.2172
0.03
PPARG
8.3333a
4.6667b
1.4530
0.04
a
b
SCD
8.3333
4.6667
1.2247
0.02
PNPLA2
7.8333
5.1667
1.7105
0.16
x
y
IGF2
8.0000
5.0000
1.5694
0.09
IGF1
8.6667a
4.3333b
1.2910
0.01
IGF1R
7.3333
5.6667
1.6833
0.35
a–b
Means within a row without common superscript differ (P < 0.05)
x–y
Means within a row without common superscript represent tendencies (P ≥ 0.05 and P
≤ 0.10)
1
UCP1 = uncoupling protein 1, ADIPOQ = adiponectin, CEBPA = CCAAT enhancer
binding protein alpha, PPARg = peroxisome proliferator activated receptor gamma, SCD
= stearoyl-CoA desaturase, PNPLA2 = patatin-like phospholipase domain containing 2,
IGF2 = insulin-like growth factor 2, IGF1 = insulin-like growth factor 1, IGF1R = IGF1
receptor .
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Table 3.18

Fetal immunohistochemistry of Longissimus dorsi (LM) with number of
primary to secondary fibers (Prime:Sec), number of PAX7 activated nuclei
to total nuclei (PAX7:Nuclei), total number of nuclei to number of
myofibers (Nuclei:Fiber ), and cross-sectional areas of primary and
secondary fibers (Prime CSA; Sec CSA) of calves CON (n=6), MEL (n=6).

Longissimus dorsi Immunohistochemistry
Treatment
Gene
CON
MEL
SEM
P Value
1
Prime:Sec
0.17
5.3645
6.1296
0.5060
2
x
y
PAX7:Nuclei
0.07
0.1285
0.2042
0.0356
3
Nuclei:Fiber
0.22
0.6716
0.5922
0.0592
4
Prime CSA
0.92
517.7500
535.4900
181.1200
5
Sec CSA
0.57
635.4700
469.1600
281.0800
x–y
Means within a row without common superscript represent tendencies (P ≥ 0.05 and P
≤ 0.10)
1
Ratio of primary to secondary myofibers (Primary fiber total/Secondary fiber total)
2
Ratio of PAX7 activated nuclei to total nuclei (PAX7 total/Nuclei total)
3
Ratio of nuclei total to number of total myofibers (Nuclei total/Myofiber total)
4-5
Cross-sections area of primary and secondary myofibers (µm)

71

P > 0.45

Figure 3.1

Fetal umbilical artery composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA), in milligrams per
kilogram, from fetuses harvested from CON (n=6) vs. MEL (n=6) treated
dams.
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P > 0.14

Figure 3.2

Fetal umbilical vein composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA), in milligrams per
kilogram, from fetuses harvested from CON (n=6) vs. MEL (n=6) treated
dams.
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P > 0.27

Figure 3.3

Fetal perirenal fat composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA), in milligrams per
kilogram, from fetuses harvested from CON (n=6) vs. MEL (n=6) treated
dams.
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P > 0.22

Figure 3.4

Fetal trunk plasma composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA), in milligrams per
kilogram, from fetuses harvested from CON (n=6) vs. MEL (n=6) treated
dams.

75

P > 0.49

Figure 3.5

Maternal plasma composition of saturated (SFA), monounsaturated
(MUFA), and polyunsaturated fatty acids (PUFA), in milligrams per
kilogram, from fetuses harvested from CON (n=6) vs. MEL (n=6) treated
dams.
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P = 0.56

Figure 3.6

Body weight average from fetuses harvested from CON (n=6) vs. MEL
(n=6) treated dams.
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P = 0.10
y
x

Figure 3.7

Fetal Longissimus dorsi average weight (kg) from fetuses harvested from
CON (n=6) vs. MEL (n=6) treated dams. x–y Means within a row without
common superscript represent tendencies (P ≥ 0.05 and P ≤ 0.10)
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P = 0.21

Figure 3.8

Fetal Longissimus dorsi average circumference (cm) from fetuses
harvested from CON (n=6) vs. MEL (n=6) treated dams. x–y Means within a
row without common superscript represent tendencies (P ≥ 0.05 and P ≤
0.10)
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P = 0.07
y
x

Means
within a
row
without
common
superscri
pt
represent

Figure 3.9

tendenci
Fetal Longissimus dorsi average length (cm) from fetuses harvested from
CON (n=6) vs. MEL (n=6) treated dams. x–y Means within a row without
es (P ≥
common superscript represent tendencies (P ≥ 0.05 and P ≤ 0.10)
0.05 and
P≤
0.10).07
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P = 0.32
Means
within a
row
without
common
superscri
pt
represent
Figure 3.10

tendenci
Fetal perirenal adipose tissue average weight (kg) from fetuses harvested
from CON (n=6) vs. MEL (n=6) treated dams.
es (P ≥
0.05 and
P≤
0.10).07
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P = 0.23

Figure 3.11

Relative expression (mRNA abundance) of Insulin-Like Growth factor 1 in
Longissimus dorsi, from fetuses harvested from CON (n=6) vs. MEL (n=6)
treated dams.
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P = 0.31

Figure 3.12

Relative expression (mRNA abundance) of Insulin-Like Growth factor 1
receptor in Longissimus dorsi, from fetuses harvested from CON (n=6) vs.
MEL (n=6) treated dams.
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P = 0.24

Figure 3.13

Relative expression (mRNA abundance) of Insulin-Like Growth factor 2 in
Longissimus dorsi, from fetuses harvested from CON (n=6) vs. MEL (n=6)
treated dams.
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P = 0.35

Figure 3.14

Relative expression (mRNA abundance) of Insulin-Like Growth factor 2
receptor in Longissimus dorsi, from fetuses harvested from CON (n=6) vs.
MEL (n=6) treated dams.
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P = 0.38

Figure 3.15

Relative expression (mRNA abundance) of bone morphogenetic protein in
Longissimus dorsi, from fetuses harvested from CON (n=6) vs. MEL (n=6)
treated dams.
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P = 0.02
b

a

Figure 3.16

Relative expression (mRNA abundance) of cystatin in Longissimus dorsi,
from fetuses harvested from CON (n=6) vs. MEL (n=6) treated dams. a–b
Means within a row without common superscript differ (P < 0.05)
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P = 0.28

Figure 3.17

Relative expression (mRNA abundance) of lysyl oxidase in Longissimus
dorsi, from fetuses harvested from CON (n=6) vs. MEL (n=6) treated
dams.

88

P = 0.03

b

a

Figure 3.18

Fetal Relative expression (mRNA abundance) of adenosine
monophosphate-activated protein kinase-α in Longissimus dorsi, from
fetuses harvested from CON (n=6) vs. MEL (n=6) treated dams. a–b Means
within a row without common superscript differ (P < 0.05)
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P = 0.93

Figure 3.19

Fetal Relative expression (mRNA abundance) of myogenic factor 5 in
Longissimus dorsi, from fetuses harvested from CON (n=6) vs. MEL (n=6)
treated dams.
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P = 0.17

Figure 3.20

Fetal Relative expression (mRNA abundance) of myogenin in Longissimus
dorsi, from fetuses harvested from CON (n=6) vs. MEL (n=6) treated
dams.

91

P = 0.59

Figure 3.21

Fetal Relative expression (mRNA abundance) of myogenic differentiation
1 in Longissimus dorsi, from fetuses harvested from CON (n=6) vs. MEL
(n=6) treated dams.
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P = 0.21

Figure 3.22

Fetal Relative expression (mRNA abundance) of CCAAT enhancer binding
protein alpha in Longissimus dorsi, from fetuses harvested from CON
(n=6) vs. MEL (n=6) treated dams.
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P = 0.51

Figure 3.23

Fetal Relative expression (mRNA abundance) of stearoyl-CoA desaturase
in Longissimus dorsi, from fetuses harvested from CON (n=6) vs. MEL
(n=6) treated dams.

94

P = 0.69

Figure 3.24

Fetal Relative expression (mRNA abundance) of peroxisome proliferator
activated receptor gamma in Longissimus dorsi, from fetuses harvested
from CON (n=6) vs. MEL (n=6) treated dams.

95

P = 0.21

Figure 3.25

Fetal Relative expression (mRNA abundance) of patatin-like phospholipase
domain containing 2 in Longissimus dorsi, from fetuses harvested from
CON (n=6) vs. MEL (n=6) treated dams.

96

P = 0.62

Figure 3.26

Fetal Relative expression (mRNA abundance) of uncoupling protein 1 in
perirenal adipose tissue, from fetuses harvested from CON (n=6) vs. MEL
(n=6) treated dams.

97

P = 0.01

a

b

Figure 3.27

Fetal Relative expression (mRNA abundance) of adiponectin in perirenal
adipose tissue, from fetuses harvested from CON (n=6) vs. MEL (n=6)
treated dams. a-b Significance of means without common letters (P ≤ 0.05).

98

P = 0.03
a

b

Figure 3.28

Fetal Relative expression (mRNA abundance) of CCAAT enhancer binding
protein alpha in perirenal adipose tissue, from fetuses harvested from CON
(n=6) vs. MEL (n=6) treated dams. a-b Significance of means without
common letters (P ≤ 0.05)
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P = 0.04

a

b

Figure 3.29

Fetal Relative expression (mRNA abundance) of peroxisome proliferator
activated receptor gamma in perirenal adipose tissue, from fetuses
harvested from CON (n=6) vs. MEL (n=6) treated dams. a-b Significance of
means without common letters (P ≤ 0.05)

100

P = 0.02

a

b

Figure 3.30

Fetal Relative expression (mRNA abundance) of stearoyl-CoA desaturase
in perirenal adipose tissue, from fetuses harvested from CON (n=6) vs.
MEL (n=6) treated dams. a-b Significance of means without common letters
(P ≤ 0.05).

101

P = 0.16

Figure 3.31

Fetal Relative expression (mRNA abundance) of patatin-like phospholipase
domain containing 2 in perirenal adipose tissue, from fetuses harvested
from CON (n=6) vs. MEL (n=6) treated dams.

102

P = 0.01

a

b

Figure 3.32

Fetal Relative expression (mRNA abundance) of insulin-like growth factor
1 in perirenal adipose tissue, from fetuses harvested from CON (n=6) vs.
MEL (n=6) treated dams. a-b Significance of means without common letters
(P ≤ 0.05).
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P = 0.35

Figure 3.33

Fetal Relative expression (mRNA abundance) of insulin-like growth factor
1 receptor in perirenal adipose tissue, from fetuses harvested from CON
(n=6) vs. MEL (n=6) treated dams.

104

P = 0.09

x

y

Figure 3.34

Fetal Relative expression (mRNA abundance) of insulin-like growth factor
2 in perirenal adipose tissue, from fetuses harvested from CON (n=6) vs.
MEL (n=6) treated dams. x-y Significance of means without common letters
(P ≤ 0.05)

105

P = 0.17

Figure 3.35

Fetal Longissimus dorsi primary to secondary muscle fibers from fetuses
harvested from CON (n=6) vs. MEL (n=6) treated dams.

106

P = 0.07

y

x

Figure 3.36

Fetal Longissimus dorsi PAX7 activated nuclei to total nuclei from fetuses
harvested from CON (n=6) vs. MEL (n=6) treated dams. x-y Tendencies of
means without common letters (P > 0.05 and P ≤ 0.10).
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P = 0.22

Figure 3.37

Fetal Longissimus dorsi total nuclei to total muscle fibers from fetuses
harvested from CON (n=6) vs. MEL (n=6) treated dams.

108

P = 0.92

Figure 3.38

Fetal Longissimus dorsi average primary muscle fiber cross-sectional area
from fetuses harvested from CON (n=6) vs. MEL (n=6) treated dams.
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P = 0.57

Figure 3.39

Fetal Longissimus dorsi average secondary muscle fiber cross-sectional
area from fetuses harvested from CON (n=6) vs. MEL (n=6) treated dams.
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Figure 3.40

Fetal Longissimus dorsi immunohistochemistry in calves CON (n=6), MEL
(n=6). Scale bar is 200 µm in length. Image A. immunofluorescent staining
of dystrophin, C-terminal antibody (Red; PA1-37587, Thermo Scientific,
Waltham, MA). Image B. immunofluorescent staining of BA-D5, myosin
heavy chain IgG2b, (Yellow; Developmental Studies Hybridoma Bank,
University of Iowa, Iowa City, IA). Image C. immunofluorescent staining
of nuclei, Hoescht (Blue; CAT # 33342, Thermo Scientific, Waltham,
MA). Image D. immunofluorescent staining of PAX7, hybridoma cell
supernatant (Green; Developmental Studies Hybridoma Bank). Image E.
overlays images 1 A-D.
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CHAPTER IV
EFFECT OF MATERNAL MELATONIN SUPPLEMENTATION DURING LATE
GESTATION ON NEONATAL LOIN MUSCLE GENE EXPRESSION DURING
EARLY POSTNATAL LIFE
4.1

Abstract
Melatonin is a natural hormone that is secreted by the pineal gland and has effects

on economically important reproductive and carcass tissues including muscle and adipose
tissue. Supplemental melatonin during gestation increased postnatal weight of calves
starting at 8 weeks of age (Brockus et al., 2016). The objectives of the study were to
determine the effects of maternal melatonin supplementation during late gestation on
relative gene expression in the Longissimus dorsi (LM) of bovine offspring. Beef heifers
(n = 32) and cows (n = 25) consisting of purebred Angus, purebred Hereford, or
crossbred genetics, were bred via timed-artificial insemination and assigned to one of two
treatment groups. The treatment groups consisted of melatonin supplementation (MEL)
or without supplementation (CON). Supplementation of MEL was delivered via two- 24
mg implants with the CON receiving two placebo implants at days 180, 210, and 240 of
gestation. After day 240 of gestation, dams received no further treatments. At the time of
parturition (d 0), Longissimus dorsi biopsies of the calves were collected to undergo gene
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expression via qPCR analysis. Maternal supplementation of MEL during late gestation
resulted in no difference (P > 0.05) in calf birth weights between treatments, however,
calves from MEL treated dams averaged 20 kg body weight increase (P = 0.03) at d 195
compared to calves from CON dams. There were no differences (P > 0.05) between
treatment groups for observed LM adipogenic and fibrogenic relative gene expressions.
Though calves from MEL treated dams have a tendency for increased (P = 0.09) AMPK
relative expression at birth, with increased MyoD (P = 0.04), IGF2 (P = 0.01), and a
tendency for increased IGF1 (P = 0.05), by d 195 of age. At birth and d195, specific
genes that are responsible for muscle metabolism and accretion have shown to be
increased that can aid in superior muscle growth compared to calves from CON dams.
Further testing of important time periods such as weaning, yearling, and harvesting could
provide important data into the long-term changes as the animal continues to grow and
develop until reaching market.
4.2

Introduction
With the rapidly increasing global population, the need for improving the

efficiency of livestock in terms of meat production is vital. Prenatal myogenic and
adipogenic development are a large determinant of the animal’s future postnatal
production potential. Economically important tissues such as muscle and adipose are of a
lower developmental priority compared to vital organs and nervous tissues (Zhu et al.,
2006; Du et al., 2010). This leaves muscle and adipose tissue development particularly
susceptible to the prevailing nutritional environment in utero (Zhu et al., 2006; Du et al.,
2010). Stimuli and insults during the development of these tissues can set the stage for
increased production efficiency, maximal growth, and superior carcasses, or lead to
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impaired growth, inferior carcass composition, and increased risk of morbidity and
mortality. Fetal programming is a change in the growth trajectory due to a stimulus or
insult during a critical time in development for the fetus resulting in persisting effects into
the postnatal phases of life or production (Nathanielsz et al., 2007). The first of these
critical time points in growth for livestock is during prenatal development, at which point
the fetus is completely dependent on the dam for nutrients. Nutrients for the fetus are in
maternal circulation and must cross over to the fetus through the placenta. The nutritional
status of the dam can have long lasting effects on fetal development by permanently
altering the development of adipogenesis, fibrogenesis, and myogenesis (Karunaratne et
al., 2005; Rehfeldt and Kuhn, 2006; Zhu et al., 2006; Funston et al., 2010; Huang et al.,
2010; Duarte et al., 2014; Wang et al., 2017).
Approaches to prevent or rescue compromised pregnancies include identifying
agents and mechanisms to improve uteroplacental nutrient exchange and in turn augment
the in utero nutritional environment experienced by the fetus. Among these,
supplementation of melatonin has been investigated as a novel therapeutic approach to
increase uteroplacental blood flow (Lemley et al., 2012 and 2013; Brockus et al., 2016).
Melatonin is a natural hormone produced from the pineal gland and derived from
tryptophan. Melatonin has been described as having pleiotropic properties acting as a
vasodilator, strong antioxidant, and signaling molecule for regulating natural circadian
rhythm (Richter et al., 2009). The known melatonin receptors include MT1 and MT2
(Dubocovich et al., 1998, 2010) and their presence has been detected on peripheral
tissues including muscle (Stratos et al., 2012) and adipose tissue (Le Gouic et al., 1997).
In skeletal muscle, binding of melatonin to these receptors stimulates glucose transport
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into muscle cells (Ha et al., 2006), increases the number of satellite cells, reduces
inflammation, and inhibits apoptosis by modulating associated signaling pathways
(Stratos et al., 2012). Melatonin increased insulin receptor substrate-1 is phosphorylated
and the activity of phosphatidylinositol 3-kinase is increased, resulting in increased
glucose uptake (Ha et al., 2006). Studies have found melatonin to cause increased hair
follicle growth in goats (Nixon et al.,1993), cardiovascular influence (Pechanova et
al.,2014), and decreased core body temperature in humans (Krauchi et al.,1997).
However, studies looking at similar effects in cattle was lacking. A study conducted by
Brockus et al. (2016) supplemented Holstein heifers with melatonin to look at effects on
offspring blood pressure, heart rate, liver blood flow, skin temperature, and hair growth.
They found that calves from dams supplemented with melatonin during their last
trimester of gestation, had significantly higher body weights at weeks 8 and 9 of age
(Brockus et al., 2016). They hypothesized that melatonin supplementation could have
altered skeletal muscle development of the calves, providing impetus for the current
study (Brockus et al., 2016).
This lead us to investigate the effects of MEL supplementation on skeletal muscle
by collecting the entire fetal LM muscle to look at different morphometric measurements
consisting of weight, circumference, and length, as outline in Section 3.3. Maternal
supplementation of MEL during late gestation resulted in fetal LM tending to weigh more
and be longer than that of calves from CON treated dams (Section 3.4). Also, analysis
with immunohistochemistry showed calves from dams treated with MEL having a
tendency for increased PAX7 activated nuclei to total nuclei ratio. This is important as
the activation of PAX7 is required for fetal myoblast formation, and PAX7+ progenitor
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cells act as a foundation and give rise to myogenic cells necessary for fetal skeletal
muscle accretion (Hutcheson et al., 2009). Skeletal muscle being a heterogenous tissue,
and MEL known effects on adipose metabolism (Elliott et al., 1989; Puchalski et al.,
2003; Raskind et al., 2007; Korhonen et al., 2008), lead us to collect plasma samples
consisting of: fetal umbilical artery and vein plasma, fetal trunk plasma, and maternal
plasma a long with fetal perirenal (PR) adipose tissue, as outlined in Section 3.3. To
summarize the findings, calves from MEL supplemented dams had decreased adipogenic
relative gene expression in PR adipose tissue (Table 3.17). To investigate the effects on
calves from MEL treated dams, we decided to use a longitudinal approach looking at the
postnatal development of their offspring at birth and d 195 of age.
Therefore, our hypothesis was that increased maternal melatonin concentration
during late gestation will lead to calves with altered metabolic programing of postnatal
skeletal muscle. Additionally, the increased uterine blood flow will improve postnatal
growth by programming increased myogenic mRNA gene expression in postnatal skeletal
muscle. The specific objectives of the study were to determine the effects of maternal
melatonin supplementation during late gestation on gene expression in the Longissimus
dorsi (LM) of bovine offspring.
4.3
4.3.1

Materials and Methods
Animal Care and Treatment
The current study was conducted under an approved Mississippi State University

Institutional Animal Care and Use Committee protocol (#16-036).
A total of 87 heifers and 65 cows that consisted of purebred Angus, purebred
Hereford, or crossbred genetics, were bred via timed-artificial insemination (AI) at the H.
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H. Leveck Animal Research Center. Heifers were bred on December 10, 2015, and cows
were bred on December 21, 2015. At 120 days post-AI, heifers and cows were examined
via ultrasonography to confirm pregnancy. This resulted in 32 heifers and 25 cows with
confirmed conception. Then dams were blocked by bodyweight and randomly assigned to
one of 2 maternal treatment groups. The 2 maternal treatment groups consist of a
melatonin treatment (MEL; n = 29) and a no melatonin treatment (CON; n = 28). The
MEL group was administered two ear impants (MelatoninImplants.com) containing
24mg MEL each, every 30 days starting at d 180 of gestation (baseline) and ending on d
240 of gestation. The MEL implant on d 240 of gestation was expected to provide
increased maternal MEL concentration approximately till d 270 of gestation. After d 270
of gestation, all dams received no further treatments throughout the study. Both maternal
treatment groups were managed the same throughout the study and had access to similar
dietary regimes with ad libitum water access. Within 24 hours of parturition (d 0), calves
were weighed, tattooed, ear tagged, serum and plasma collected, and live muscle biopsies
of the LM taken with subsequent samples collected at 195 d of age (d 195).
4.3.2

Longissimus dorsi biopsy collection
Muscle biopsy samples were collected from 35 calves on day 0 of age (CON = 17,

MEL = 18) to serve as a biological baseline for the study. At day 195 of age, 31 calves
(CON = 15, MEL = 16) had a second LM biopsy collected to analyze for changes in
mRNA gene expression. Four of the calves were removed from this study because they
required special management and their day 0 data will not be included. The landmark for
the biopsies was located behind the 13th rib, in the middle of the muscle relative to the
lumbar vertebra, on the left side of each calf. After cleaning the biopsy site, 1 cc of
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Lidocaine (Aspen, Liberty, MO) was injected to provide local analgesia. After allowing
sufficient time for the anesthetic, a 14-gauge piercing needle was used to penetrate fully
through the skin. Then three biopsies of approximatly1g each of LM tissue were
extracted using a 14-gauge x 9 cm Quick-Core® Biopsy Needle (COOK, Bloomington,
IN) behind the 13th rib. The biopsy needle was inserted through the punctured skin at a
45-degree angle relative to the LM fibers. Tissue samples were stored in cryotubes at 80°C until further analysis.
4.3.3
4.3.3.1

Longissimus dorsi Analysis of Relative Gene Expression
QuantiNova™ SYBR® Green PCR Kit
Nucleic acids were isolated from the LM biopsy samples using 700 μl of QIAzol®

Lysis Reagent (QIAGEN, Hilden, Germany), followed by purification with the use of
RNA using a miRNeasy® Mini Kit (QIAGEN, Hilden, Germany). Extracted total RNA
was quantified using a NanoDrop One spectrophotometer (Thermo scientific, Waltham,
MA). Samples exhibiting 260 nm/280 nm ratios between 1.9 and 2.1 were deemed
acceptable for downstream procedures and stored at -80°C. For each sample, duplicate
cDNA synthesis reactions were conducted using 100 ng of total RNA using
QuantiNova™ Reverse Transcription Kits (QIAGEN, Hilden, Germany) according to the
manufacturers protocol. The genes of interest for LM tissue cystatin (CYS), adenosine
monophosphate-activated protein kinase-α (AMPK). Beta actin was used as a
housekeeping gene. Gene specific primers for the genes of interest (Table 4.1) were
designed and validated for quantitative PCR (qPCR). Primer efficiencies were
determined by plotting the threshold cycle versus the log of the input concentrations for
8, 10-fold serial dilutions of pooled LM muscle cDNA. Primer sets and assays with
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efficiencies between 0.9 and 1.1 were considered acceptable for real time PCR analysis.
Each of the duplicate cDNA samples were subjected to duplicate qPCR reactions using
QuantiNova™ SYBR® Green PCR Kit (QIAGEN, Hilden, Germany). A master mix
containing SYBR® Green, forward and reverse primers (diluted 1:20), and ROX reference
dye along with 112.5 ng of cDNA was pipetted into a 96-well MicroAmp® Fast Optical
Reaction Plate (Applied Biosystems, Foster City, CA). The plate was then covered with
Masterclear real-time PCR Film (Eppendorf, Hamburg, Germany), briefly vortexed and
centrifuged, then placed in QuantiStudio™ 3 (Applied Biosystems, Foster City, CA) for
real-time qPCR analysis. Thermal cycling parameters used consisted of: a hold stage at
95°C for 2 minutes; PCR stage with step 1 at 95°C for 5 seconds followed by step 2 at
60°C for 10 seconds for 50 cycles; with a melting curve stage have step 1 at 95°C for 1
second then step 2 60°C for 20 seconds and step 3 (dissociation) at 95°C for 1 second
(capturing every 0.1°C/s). Replicate threshold cycle (CT) values were averaged and used
for relative quantification using the 2−ΔΔCT method (Livak and Schmittgen, 2001).
4.3.3.2

TaqMan™ fast advanced master mix
Nucleic acids were isolated from the LM biopsy samples using 700 μl of

QIAzol® Lysis Reagent (QIAGEN, Hilden, Germany), followed by purification with the
use of RNA using a miRNeasy® Mini Kit (QIAGEN, Hilden, Germany). Extracted total
RNA was quantified using a NanoDrop One spectrophotometer (Thermo scientific,
Waltham, MA). Samples exhibiting 260 nm/280 nm ratios between 1.9 and 2.1 were
deemed acceptable for downstream procedures and stored at -80°C. For each sample,
duplicate cDNA synthesis reactions were conducted using 100 ng of total RNA using
QuantiNova™ Reverse Transcription Kits (QIAGEN, Hilden, Germany) according to the
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manufacturer protocol. The genes of interest for LM were insulin-like growth factor 1
(IGF1), IGF1 receptor (IGF1R), insulin-like growth factor 2 (IGF2), IGF2 receptor
(IGF2R), myogenic factor 5 (Myf5), myogenin (MyoG), myogenic differentiation 1
(MyoD), stearoyl-CoA desaturase (SCD), peroxisome proliferator activated receptor
gamma (PPARg), and patatin-like phospholipase domain containing 2 (PNPLA2). Beta
actin was used as a housekeeping gene. Assays for the genes of interest (Table 4.2) were
validated for efficiency and specificity prior to qPCR. Primer efficiencies were
determined by plotting the threshold cycle versus the log of the input concentrations for
8, 10-fold serial dilutions of pooled PR adipose tissue cDNA. Primer sets and assays with
efficiencies between 0.9 and 1.1 were considered acceptable for real time PCR analysis.
Complementary DNA was amplified in duplicate using TaqMan™ fast advanced master
mix (Thermo scientific, Waltham, MA). A master mix containing TaqMan™ fast
advanced master mix and gene assay was pipetted along with 37.5 ng of cDNA into a 96well MicroAmp® Fast Optical Reaction Plate (Applied Biosystems, Foster City, CA).
The plate was then covered with Masterclear real-time PCR Film (Eppendorf, Hamburg,
Germany), briefly vortexed and centrifuged, then placed in QuantiStudio™ 3 (Applied
Biosystems, Foster City, CA) for real-time qPCR analysis. Thermal cycling parameters
used consisted of: a hold stage at 50°C for 2 minutes; polymerase activation hold at 95°C
for 20 seconds; PCR stage with step 1 at 95°C for 1 second followed by step 2 at 60°C
for 20 seconds for 40 cycles. Replicate CT values were averaged and used for relative
quantification using the 2−ΔΔCT method (Livak and Schmittgen, 2001).
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4.3.4

Statistical Analysis
Gene expressions and morphometrics were analyzed using MIXED procedure of

the Statistical Analysis System (SAS software version 9.4, SAS Institute, Cary, NC,
USA). Where the model statement included: treatment, calf sex, treatment x calf sex
interaction, parity, treatment x parity interaction, and breed of dam, treatment x breed,
calf day of age, and treatment x day interaction. Data found to be nonnormally distributed
were tested using the Wilcoxon rank sum test. Gestation length served as covariate for d
0 with d 195 having age of calf as covariate. Least square means and standard error of the
means were reported. Pairwise comparisons between the least squares means of the factor
levels were computed using the PDIFF option of the LSMEANS statement. Statistical
significance was determined at P ≤ 0.05, and P-values falling within P > 0.05 and P ≤
0.10 were considered a trend.
4.4
4.4.1

Results
D 0 Morphometric Analysis
Birth weight was not different (P > 0.05) in calves from MEL treated dams

compared to calves from CON treated dams (Table 4.3; Figure 4.1).
4.4.2

D 0 Longissimus dorsi Relative Gene Expression Analysis
At d 0, LM relative gene expression did not differ (P > 0.05) for the following:

CYS, IGF1, IGF1R, IGF2, IGF2R, MyoG, MyoD, Myf5, PPARg, PNPLA2, or SCD
between calves from MEL compared to CON dams (Table 4.4, 4.5; Figures 4.3, 4.54.14). At d 0, LM relative gene expression of AMPK tended to be increased (P = 0.09) in
calves from MEL compared to CON dams (Table 4.4; Figure 4.4).
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4.4.3

Day 195 Morphometric Analysis
At d 195, calf body weight was increased (P = 0.03) in calves from MEL treated

dams compared to calves from CON treated dams (Table 4.3 Figure 4.2).
4.4.4

Day 195 Longissimus dorsi Relative Gene Expression Analysis
At d 195, LM relative gene expression did not differ (P > 0.05) for the following:

CYS, AMPK, IGF1R, IGF2R, MyoG, Myf5, PPARg, PNPLA2, or SCD between calves
from MEL compared to CON dams (Table 4.4, 4.5; Figures 4.3, 4.4, 4.6, 4.8, 4.9, 4.114.14). However, LM relative gene expression was increased for IGF2 (P = 0.01) and
MyoD (P = 0.04) with IGF1 tending to be increased (P = 0.05) between calves born from
MEL treated dams compared to CON dams (Tables 4.5; Figures 4.5, 4.7, 4.10).
4.5

Discussion
Brockus and colleagues, found that Holstein calves from MEL treated dams had

no difference in birth weight but had an increased body weight starting at 8 weeks of age
compared to calves from CON dams (2016). The authors believed that MEL
supplementation to Holstein dams during late gestation may have caused a programmed
response leading to a change in fetal skeletal muscle development that potentially caused
the increased weight gain (Brockus et al., 2016). To investigate this hypothesis, we
conducted twelve fetal necropsies collecting LM muscle, perirenal (PR) adipose,
umbilical artery and vein plasma, fetal trunk plasma, and maternal plasma samples, as
outlined in Section 3.3. The reason for examining fetal muscle and adipose tissue was to
observe if MEL supplementation to dams during late gestation had any effects on
myogenesis and adipogenesis. The full report of the results from the fetal portion of this
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study are shown in Section 3.4. To summarize, maternal supplementation of MEL during
late gestation does impact fetal calf LM muscle and PR adipose tissue development by d
240 of gestation. The next step to investigate the claim of increased postnatal calf body
weight lead us to conducting a postnatal trial.
In this postnatal study, there was no difference in calf birth weights between
treatment groups, which is consistent with the findings of Brockus et al. (2016).
However, calves born from MEL treated dams at d 195 weighed an average of 20 kg
more than calves from CON dams. This supports the findings of Brockus and colleagues
as they observed Holstein calves from MEL treated dams to have increased body weights
starting at 8 weeks of age compared to calves from CON dams (2016). Live biopsies of
LM muscle tissue were collected at d 0 and d 195 of age to look at postnatal relative gene
expression of myogenic, adipogenic, and fibrogenic genes as well as genes responsible
for muscle and adipose metabolism (Tables 4.1, 4.2).
Upon qPCR analysis of cDNA from d 0 LM muscle tissue, supplementation of
MEL during late gestation caused no change in myogenic or adipogenic relative gene
expression compared to that of CON, which is consistent with the fetal results in Section
3.4. However, at the time of birth, LM tissue of calves from MEL treated dams had no
difference (P > 0.05) in CYS relative gene expression compared to calves from CON
dams. This is surprising as MEL supplementation lead to fetal calves at 240 days of
gestation with increased (P = 0.02) CYS relative gene expression compared to calves
from CON dams (Table 3.15). The reason behind the change in expression between 240
days of gestation to birth and the implications are unclear. After analysis of metabolic
related genes in LM tissue, we found that IGF1, IGF1R, IGF2, and IGF2R were not
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different between treatment groups apart from AMPK, which tended to be increased (P =
0.09). This is identical to fetal results outlined in Section 3.4 except for AMPK which
was significantly increased (P = 0.03) in fetal calves from MEL treated dams. Based on
these results at the time of birth, calves from MEL supplemented dams had similar
myogenic, adipogenic, and fibrogenic relative gene expression to that of calves from
CON dams. However, the enhanced LM tissue energy metabolism provided by the
elevated AMPK levels could support superior muscle accretion.
To further investigate the observed increase in d 195 body weight, we conducted
qPCR analysis of cDNA from d 195 LM muscle tissue. There were no changes in calf
LM myogenic, adipogenic, and fibrogenic relative gene expressions; except for MyoD,
which was increased in calves born from MEL treated dams. The postnatal expression of
MyoD in skeletal muscle is involved with satellite cells differentiation (Grand and
Rudnicki, 2007). In the normal, uninjured postnatal animal, MyoD and other myogenic
regulatory factor gene expressions are either very low or undetectable in quiescent
satellite cells (Beilhartz et al., 1992; Buonanno et al., 1992; Eftimie et al., 1991).
However, muscle stress caused by weight bearing or trauma results in the activation of
satellite cells from a quiescent state to a proliferative state (Grand and Rudnicki, 2007).
The activated satellite cells then begin to express increased levels of MyoD, which
ultimately causes them to differentiate into myoblasts and then fuse with myofibers to
help with myofiber regeneration (Koishi et al., 1995; Yablonka-Reuveni, 1995; Dhawan
and Rando, 2005; Grand and Rudnicki, 2007). The increased LM relative gene
expression of MyoD in d 195 calves born from MEL treated dams could aid in muscle
hypertrophy and regeneration supporting enhanced muscle accretion compared to calves
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from CON dams. Lastly, there were no changes in IGF1R, IGF2R, or AMPK in d 195
calf LM between treatment groups. Although, IGF2 was increased (P = 0.01) in d 195
calves born from MEL treated dams and they had a tendency for increased IGF1 (P =
0.05) compared to calves from CON dams. In skeletal muscle growth and development,
IGF2 is the predominant IGF in fetal development with IGF1 being the primary growth
factor responsible for increased postnatal protein synthesis and muscle hypertrophy
(Florini et al., 1991; Haig and Graham, 1991; Braxton et al., 1993; Bass et al., 1999; Le
Roith et al., 2001; Gluckman and Pinal, 2003; Gonzalez et al., 2013; Wang and Mitch,
2014). In fetal skeletal muscle, IGF2 assists in myoblast cell growth and differentiation
and via the mTOR pathway (Erbay et al., 2003; Glass, 2010; Dai et al., 2011;
Hornberger, 2011; Ge and Chen, 2012). Current literature on the importance of IGF2 in
postnatal animal is currently lacking as levels of IGF2 in postnatal animals is very low
(Clark et al., 2015). However, some literature observing the effects of mutations that
caused elevated levels of postnatal IGF2 have shown to increase skeletal muscle mass of
pigs (Gardan et al., 2008a; Gardan et al., 2008b). The effects of IGF1 on postnatal muscle
accretion has been shown to be a combination of satellite cell activation and increasing
protein synthesis in myofibers (Barton-Davis et al., 1999; Machida and Booth, 2004).
In Summary, maternal supplementation of MEL during late gestation does impact
LM muscle relative gene expression of calves at birth and d 195 of age. At birth and
d195, specific genes that are responsible for muscle metabolism and accretion have
shown to be increased. With increased muscle energy metabolism and protein synthesis,
these calves could support superior muscle growth compared to calves from CON dams.
One limitation to this study is the absence of postnatal LM samples for
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immunohistochemical (IHC) analysis and perirenal adipose for qPCR and IHC analysis.
Future research will be needed to provide additional information on the effects of MEL
supplementation to dams during late gestation on their offspring’s performance from
birth up to slaughter.
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Table 4.1

1

Accession, sequences, amplicon length, and efficiency of primers used for
QuantiNovaTM SYBR® Green real-time PCR quantification of Longissimus
dorsi gene expression.

Gene1

Accession

CYS

NM_174029.1

AMP
K
Beta
Actin

Forward Primer

Reverse Primer

NM_00110980
2

GTGGAGCTTGGCCGGACTAC
AT
ACCATTCTTGGTTGCTGAAAC
TC

CACCAGGTTGATGGTGTTCAT
CC
CACCTTGGTGTTTGGATTTCT
G

NM_173979

GTCGACACCGCAACCAGTT

AAGCCGGCCTTGCACAT

Amplico
n Size

Efficiency

143

1.04

80

0.99

85

0.94

CYS = cystatin, AMPK = adenosine monophosphate-activated protein kinase-α.
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Table 4.2

Assays, accession, amplicon length, and efficiency of primers used for
TaqMan® real-time PCR quantification of Longissimus dorsi gene
expression.

Gene1
Assay ID
Accession
Amplicon Size Efficiency
Beta Actin Bt03279174_g1
NP_776404
141
0.96
Myf5
Bt03223134_m1
NP_776541
98
0.95
MyoG
Bt03258928_m1
NP_001104795.1
96
0.96
MyoD
Bt03244740_m1
NP_001035568.2
84
0.95
SCD
Bt04307478_m1
NP_776384.3
89
0.97
PPARg
Bt03217547_m1
NP_851367.1
85
0.93
PNPLA2
Bt03234128_m1
NP_001039470.1
77
0.98
IGF1
Bt03252282_m1
NM_001077828.1 65
0.99
IGF1R
Bt03649217_m1
NP_001231541.1
70
0.93
IGF2
Bt03259225_m1
NP_776512.2
54
0.95
IGF2R
Bt03223452_m1
NP_776777.1
57
0.97
1
Myf5 = myogenic factor 5, MyoG = myogenin, MyoD = myogenic differentiation 1,
SCD = stearoyl-CoA desaturase, PPARg = peroxisome proliferator activated receptor
gamma, PNPLA2 = patatin-like phospholipase domain containing 2, IGF1 = insulin-like
growth factor 1, IGF1R = IGF1 receptor, IGF2 = insulin-like growth factor 2, IGF2R =
IGF2 receptor.
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Table 4.3

Morphometric body weight measurements of newborn (d0) calves and at
195 days of age (d195) from heifers and cows treated with CON (n=17)
and MEL (n=18).

Morphometric Measurements
Treatment
Measurements
CON
MEL
SEM
d0 BW (kg)
29.2962
30.0535
2.1489
a
b
d195 BW (kg)
203.6800
222.9200
8.4327
a–b
Means within a row without common superscript differ (P < 0.05)
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P Value
0.73
0.03

Table 4.4

QuantiNovaTM SYBR® Green real-time PCR quantification of day 0 and
day 195 of age calf Longissimus dorsi (LM) PCR relative expression of
IGF1, IGF1R, IGF2, IGF2R, BMP, CYS, LOX, and AMPK of calves CON
(n=15) and MEL (n=12).

Longissimus dorsi PCR Relative Expression
Treatment
1
Gene
Day
CON
MEL
SEM
P Value
CYS
0
13.6312
14.0463
1.8188
0.82
x
y
AMPK
0
11.6610
16.0537
2.3984
0.09
CYS
195
12.9846
15.7637
2.1501
0.22
AMPK
195
9.7948
13.4842
2.1658
0.11
x–y
Means within a row without common superscript represent tendencies (P ≥ 0.05 and P
≤ 0.10)
1
CYS = cystatin, AMPK = adenosine monophosphate-activated protein kinase-α.
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Table 4.5

TaqMan® real-time PCR quantification of Fetal Longissimus dorsi (LM)
PCR relative expression of IGF1, IGF1R, IGF2, IGF2R, BMP, CYS, LOX,
and AMPK of calves CON (n=15) and MEL (n=12).

Longissimus dorsi PCR Relative Expression
Treatment
Gene
Day
CON
MEL
SEM
P Value
IGF1
0
16.3649
12.6753
2.4820
0.16
IGF1R
0
15.1188
13.8071
2.8333
0.65
IGF2
0
15.3318
11.2373
3.1644
0.21
IGF2R
0
12.2895
15.1951
3.3600
0.40
MyoG
0
10.5495
14.4845
3.3174
0.25
MyoD
0
13.2074
15.2774
3.0557
0.51
Myf5
0
13.4810
13.5475
2.6275
0.98
PPARG
0
14.6599
12.4148
2.8657
0.44
PNPLA2
0
13.5073
15.5713
2.4724
0.42
SCD
0
13.6577
9.9399
3.1103
0.25
x
y
IGF1
195
11.3291
16.3203
2.3612
0.05
IGF1R
195
13.8416
15.2951
2.7761
0.61
a
b
IGF2
195
10.8386
19.1387
2.6646
0.01
IGF2R
195
15.2453
16.0937
2.7091
0.76
MyoG
195
14.7130
18.1307
2.5274
0.20
a
b
MyoD
195
12.5768
18.7497
2.8189
0.04
Myf5
195
13.0385
14.1356
2.9276
0.71
PPARG
195
14.4667
15.5676
3.0531
0.72
PNPLA2
195
13.8538
13.5899
2.6193
0.92
SCD
195
13.7654
15.6272
2.5418
0.47
a–b
Means within a row without common superscript differ (P < 0.05)
x–y
Means within a row without common superscript represent tendencies (P ≥ 0.05 and P
≤ 0.10)
1
Myf5 = myogenic factor 5, MyoG = myogenin, MyoD = myogenic differentiation 1,
CEBPA = CCAAT enhancer binding protein alpha, SCD = stearoyl-CoA desaturase,
PPARg = peroxisome proliferator activated receptor gamma, PNPLA2 = patatin-like
phospholipase domain containing 2, IGF1 = insulin-like growth factor 1, IGF1R = IGF1
receptor, IGF2 = insulin-like growth factor 2, IGF2R = IGF2 receptor.
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P = 0.73

Figure 4.1

Birth weight (d 0) average from offspring born from CON (n=15) or MEL
(n=12) treated dams.

140

P = 0.03
b
a

Figure 4.2

Body weight (d 195) average from offspring born from CON (n=15) or
MEL (n=12) treated dams. a–b Means within a row without common
superscript differ (P < 0.05)

141

P = 0.82

Figure 4.3

P = 0.22

Relative expression (mRNA abundance) of cystatin in Longissimus dorsi
from day 0 and day 195 offspring born from CON (n=15) or MEL (n=12)
treated dams.

142

y
x

P = 0.09

Figure 4.4

P = 0.11

Relative expression (mRNA abundance) of adenosine monophosphateactivated protein kinase-α in Longissimus dorsi from day 0 and day 195
offspring born from CON (n=15) or MEL (n=12) treated dams. x–y Means
within a row without common superscript represent tendencies (P ≥ 0.05
and P ≤ 0.10)
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y
x

P = 0.16

Figure 4.5

P = 0.05

Relative expression (mRNA abundance) of Insulin-Like Growth factor 1 in
Longissimus dorsi from day 0 and day 195 offspring born from CON
(n=15) or MEL (n=12) treated dams. x–y Means within a row without
common superscript represent tendencies (P ≥ 0.05 and P ≤ 0.10)

144

P = 0.61

P = 0.65

Figure 4.6

Relative expression (mRNA abundance) of Insulin-Like Growth factor 1
receptor in Longissimus dorsi from day 0 and day 195 offspring born from
CON (n=15) or MEL (n=12) treated dams.
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b
a

P = 0.01

P = 0.21

Figure 4.7

Relative expression (mRNA abundance) of Insulin-Like Growth factor 2 in
Longissimus dorsi from day 0 and day 195 offspring born from CON
(n=15) or MEL (n=12) treated dams. a–b Means within a row without
common superscript differ (P < 0.05)
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P = 0.76

P = 0.40

Figure 4.8

Relative expression (mRNA abundance) of Insulin-Like Growth factor 2
receptor in Longissimus dorsi from day 0 and day 195 offspring born from
CON (n=15) or MEL (n=12) treated dams.

147

P = 0.20

P = 0.25

Figure 4.9

Relative expression (mRNA abundance) of myogenin in Longissimus dorsi
from day 0 and day 195 offspring born from CON (n=15) or MEL (n=12)
treated dams.

148

b
a

P = 0.04

P = 0.51

Figure 4.10

Relative expression (mRNA abundance) of myogenic differentiation 1 in
Longissimus dorsi from day 0 and day 195 offspring born from CON
(n=15) or MEL (n=12) treated dams. a–b Means within a row without
common superscript differ (P < 0.05)

149

P = 0.71

P = 0.98

Figure 4.11

Relative expression (mRNA abundance) of myogenic factor 5 in
Longissimus dorsi from day 0 and day 195 offspring born from CON
(n=15) or MEL (n=12) treated dams.
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P = 0.72

P = 0.44

Figure 4.12

Relative expression (mRNA abundance) of peroxisome proliferator
activated receptor gamma in Longissimus dorsi from day 0 and day 195
offspring born from CON (n=15) or MEL (n=12) treated dams.
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P = 0.42

Figure 4.13

P = 0.92

Relative expression (mRNA abundance) of patatin-like phospholipase
domain containing 2 in Longissimus dorsi from day 0 and day 195
offspring born from CON (n=15) or MEL (n=12) treated dams.
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P = 0.47

P = 0.25

Figure 4.14

Relative expression (mRNA abundance) of stearoyl-CoA desaturase in
Longissimus dorsi from day 0 and day 195 offspring born from CON
(n=15) or MEL (n=12) treated dams.
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